

Genome-wide identification and phenotypic characterization of seizure-associated copy number variations in 741,075 individuals

Received: 3 August 2022

Accepted: 16 June 2023

Published online: 20 July 2023

 Check for updates

Ludovica Montanucci^{1,170}, David Lewis-Smith^{2,3,4,5,170}, Ryan L. Collins^{6,7,170}, Lisa-Marie Niestroj^{8,170}, Shridhar Parthasarathy^{4,5}, Julie Xian^{4,5}, Shiva Ganesan^{4,5}, Marie Macnee⁸, Tobias Brünger⁸, Rhys H. Thomas^{2,3}, Michael Talkowski^{6,7}, Epi25 Collaborative*, Ingo Helbig^{4,5,9}, Costin Leu^{1,10,11,12,171}✉ & Dennis Lal^{1,7,11,12,171}✉

Copy number variants (CNV) are established risk factors for neurodevelopmental disorders with seizures or epilepsy. With the hypothesis that seizure disorders share genetic risk factors, we pooled CNV data from 10,590 individuals with seizure disorders, 16,109 individuals with clinically validated epilepsy, and 492,324 population controls and identified 25 genome-wide significant loci, 22 of which are novel for seizure disorders, such as deletions at 1p36.33, 1q44, 2p21-p16.3, 3q29, 8p23.3-p23.2, 9p24.3, 10q26.3, 15q11.2, 15q12-q13.1, 16p12.2, 17q21.31, duplications at 2q13, 9q34.3, 16p13.3, 17q12, 19p13.3, 20q13.33, and reciprocal CNVs at 16p11.2, and 22q11.21. Using genetic data from additional 248,751 individuals with 23 neuropsychiatric phenotypes, we explored the pleiotropy of these 25 loci. Finally, in a subset of individuals with epilepsy and detailed clinical data available, we performed genome-wide association analyses between individual CNVs and clinical annotations categorized through the Human Phenotype Ontology (HPO). For six CNVs, we identified 19 significant associations with specific HPO terms and generated, for all CNVs, phenotype signatures across 17 clinical categories relevant for epileptologists. This is the most comprehensive investigation of CNVs in epilepsy and related seizure disorders, with potential implications for clinical practice.

An epileptic seizure is a paroxysm of symptoms and signs due to abnormally excessive or synchronous neuronal activity¹. Seizures are classified based on their characteristics and electroencephalogram (EEG) as focal-onset seizures (which start in a specific brain region) and generalized-onset seizures (which are rapidly seen across bihemispheric networks)^{1,2}. The utility of this seizure classification is that it categorizes epilepsy into syndromes and allows clinicians to make implications about disease etiology, trajectory, and response to medication. Clinical manifestations vary from whole-body convulsions with

loss of consciousness (tonic-clonic seizures), to movements involving only part of the body with variable levels of consciousness (focal motor seizure), to a brief loss of awareness (absence seizure)^{1,2}. Seizures can be provoked by head trauma, infection, or acute toxic-metabolic imbalance, or they can be spontaneous and unprovoked. Individuals who exhibit at least one unprovoked seizure with an enduring elevated risk of further seizures or who have the electroclinical features of one of a few specific epilepsy syndromes that can be diagnosed without recurrent seizures fulfill the criteria for a diagnosis of epilepsy¹.

A full list of affiliations appears at the end of the paper. *A List of authors and their affiliations appears at the end of the paper.

✉ e-mail: costin.leu@uth.tmc.edu; Dennis.Lal@uth.tmc.edu

Seizures and epilepsy are common in the general population. Neonatal seizures occur in 1.5% of neonates, febrile seizures in 2–4% of young children, and epilepsy in up to 1% of children and adolescents³. Seizures are common among individuals with neurodevelopmental disorders, affecting 21.5% of those with autism and intellectual disability and 8% with autism without intellectual disability⁴.

Copy number variants (CNVs), such as deletions and duplications, change the dosage of genomic segments and are established risk factors for various types of epilepsy^{5–14}, seizures¹⁵, and neuropsychiatric disorders^{16–19}. Large CNVs can affect multiple dosage-sensitive genes, leading to complex clinical presentations. To date, only one hypothesis-free genome-wide CNV association study (CNV-GWAS) has been reported for epilepsy²⁰. This CNV-GWAS in 10,712 individuals with epilepsy and 6,746 controls identified three genome-wide significant CNVs²⁰. High-resolution CNV screening has become routine in clinical molecular diagnostics, leading to greater detection of chromosomal abnormalities in patients²¹. Diagnostic CNVs can be identified in 1–4% of individuals with epilepsy and >10% of those with seizures and neurodevelopmental disorders^{13,20–22}. However, the pleiotropy of pathogenic CNVs, partially driven by structural properties (size, fixed vs. variable breakpoints, number of affected genes), represents a significant challenge in the clinical interpretation of CNVs, limiting their utility for disorder classification, prognostication, and the development of precision medicine treatments that specifically target the critical pathogenic gene(s) altered by the CNV. The majority of pathogenic and likely pathogenic CNVs are greater than 1 megabase (Mb) in size, and it is often unclear which gene(s) or genomic element(s) affected by the CNV contribute to one or more disorders^{23,24}. A well-powered seizure CNV discovery screen combined with detailed genotype-phenotype analyses could identify genomic segments that confer risk for seizures, identify clinical characteristics in affected patients and consequently guide genetic test interpretation.

Although many individuals with neuropsychiatric and developmental disorders have comorbid seizures, genome-wide CNV association analyses across epilepsy and seizure have yet to be reported. We hypothesized that genetic risk for seizures is shared in individuals with epilepsy diagnosed according to International League Against

Epilepsy (ILAE) criteria¹ and related neurological and neurodevelopmental disorders who also have seizures. Therefore, a joint analysis could add to the three epilepsy-associated CNV loci reported previously²⁰. To explore this hypothesis, we performed a meta-analysis of GWAS studies comprising 26,699 individuals with diagnosed epilepsy or seizures and 492,324 controls. Since both definitions are based on the presence of seizures, we refer to individuals affected by either condition as individuals with seizures from here on forward. The effective sample size of this study ($N_{\text{eff}}=101,302$) provides adequate power to identify significant associations of risk CNVs that are present in the general healthy population, therefore, do not exhibit complete penetrance. However, the analytic setup restricts the frequency in the general population to up to 1% for quality purposes. We assessed the pleiotropy of any identified seizure-associated CNV in subsequent meta-analyses of epilepsy and 238,161 independent individuals affected by a range of 23 neuropsychiatric disorders. Finally, using a subset of the seizure cohort comprising 10,880 individuals with epilepsy detailed using 214,203 Human Phenotype Ontology (HPO) annotations²⁵, we evaluated the clinical features characterizing carriers of each seizure-associated CNV.

Results

Discovery of 25 genome-wide significant seizure-associated CNVs regions

We performed a meta-analysis of 16,109 individuals with epilepsy and 8545 population controls (the Epi25 Collaborative cohort) with 10,590 individuals with seizures (not explicitly meeting diagnostic criteria for epilepsy) and 483,779 population controls, derived from an aggregated CNV dataset of 17 cohorts (neuropsychiatric disorders cohort) (see all cohorts of this study in Supplementary Table 1). The genome was scanned using 267,237 genomic segments of 200 kb size in a 10 kb sliding window approach²⁶. After applying Bonferroni correction of the threshold for a significant association in the meta-analysis and fine-mapping, we identified 25 loci associated with seizures at genome-wide significance ($P \leq 3.74 \times 10^{-6}$). All 25 loci are shown in Fig. 1 and detailed in Table 1. The 25 identified loci included 15 deletion CNVs (size range: 230 kb to 5 Mb) and ten duplication CNVs (size range:




Fig. 1 | Genome-wide meta-analysis identifies 25 CNVs associated with seizure disorders. Miami plot of the meta-analysis of the CNV genome-wide association analyses of (1) 16,109 individuals with clinically validated epilepsy vs. 8545 controls and (2) 10,590 individuals with seizure disorders vs. 483,779 controls. Dots represent $-\log_{10}$ of the meta-analysis P -values (P_{DEL} and P_{DUP} for deletions and

duplications, respectively) of the cohort-specific Fisher exact tests for the enrichment of CNVs in cases vs. controls for each a 200 kb sliding window. Genomic regions that surpassed the Bonferroni-corrected threshold for significance (red line, $\alpha = 3.74 \times 10^{-6}$) were annotated with the genomic band containing the signal. Deletions (top) and duplications (mirrored) are shown.

Table 1 | Genome-wide significantly associated CNV regions and credible intervals

Cytoband	CNV type	Hg19 Start (Mb)	Hg19 End (Mb)	Lowest P-value in region	OR [95% CI]	Credible interval containing the causal element/gene with 95% confidence	Associations with neuropsychiatric phenotypes [N]	Highest odds ratio in neuropsychiatric disorder/seizure meta-analyses (95% CI)
1p36.33	DEL	0.91	1.51	4.65E-09	23 (10-54)	910000-1510000	5	11 (5-24) CNS abnormality
1p36.33	DEL	2.02	2.49	1.95E-07	44 (14-141)	2020000-2490000	3	48 (14-170) Abnormalities of Cognition
1q44	DEL	245.29	245.86	6.59E-07	41 (13-133)	245290000-245860000	6	62 (19-207) Abnormal brain morphology
2p21-p16.3	DEL	47.5	47.85	3.00E-13	12 (7-22)	47500000-47850000	23	13 (8-24) Behavioral abnormalities
2q13	DUP	110.77	111.06	1.33E-06	3 (2-5)	110770000-111060000	6	24 (9-63) Hyperactivity
3q29	DEL	195.76	196.24	2.01E-07	40 (13-122)	195760000-196240000	0	no significant association signal
8p23.3-p23.2	DEL	0.4	5.47	1.83E-08	12 (6-25)	400000-610000 3040000-3780000 4810000-5470000	4	16 (7-39) Intellectual disability
9p24.3	DEL	0.33	0.56	1.08E-07	13 (6-29)	330000-560000	1	7 (4-12) Neurodevelopmental abnormality
9q34.3	DUP	139.21	140.12	1.67E-06	12 (5-27)	139210000-139590000 139890000-140120000	21	12 (6-25) Schizophrenia
10q26.3	DEL	133.41	134.68	3.16E-07	40 (13-125)	133410000-133740000 134370000-136480000	2	32 (10-107) Sleep disorder
15q11.2	DEL	22.74	23.28	1.02E-13	3 (2-3)	22740000-23280000	12	3 (2-4) Abnormalities of Cognition
15q11.2-q13.3	DUP	22.98	32.15	3.68E-19	27 (14-52)	24750000-25080000	23	33 (16-67) Intellectual disability
15q12-q13.1	DEL	27.93	28.23	9.85E-07	14 (6-34)	27930000-28230000	3	24 (11-52) Intellectual disability
15q13.2-q13.3	DEL	31.06	32.51	6.71E-16	14 (8-24)	31060000-32510000	17	16 (6-44) Sleep disorder
16p13.3	DUP	0.6	0.89	1.98E-13	9 (5-14)	60000-890000	23	12 (6-26) Schizophrenia
16p13.11	DEL	15.42	16.35	3.53E-17	9 (6-14)	15420000-16350000	18	13 (4-44) CNS atrophy
16p12.2	DEL	21.88	22.5	1.14E-06	4 (2-5)	21880000-22500000	6	4 (2-6) Hyperactivity
16p11.2	DEL	29.56	30.19	1.25E-11	9 (5-15)	29560000-30190000	11	13 (8-21) Intellectual disability
16p11.2	DUP	29.87	30.19	2.45E-08	6 (3-10)	29870000-30190000	12	11 (5-24) Sleep disorder
17q12	DUP	34.76	36.25	1.12E-15	15 (9-27)	34760000-35510000 35960000-36250000	14	10 (5-20) Abnormal brain morphology
17q21.31	DEL	41.08	41.45	1.98E-08	5 (3-9)	41080000-41450000	20	6 (4-10) Abnormality of the nervous system
19p13.3	DUP	1.04	1.34	2.85E-10	7 (4-12)	1040000-1340000	23	7 (4-14) Schizophrenia
20q13.33	DUP	62	62.35	7.12E-11	6 (4-10)	62000000-62350000	23	8 (5-13) CNS abnormality
22q11.21	DUP	18.99	21.54	8.73E-11	5 (3-7)	18990000-1937000 20200000-21540000 18990000-19400000	9	5 (3-7) Hyperactivity
22q11.21	DEL	18.99	21.54	1.57E-08	26 (10-65)	19670000-19960000 20650000-21540000	12	26 (9-70) Central motor dysfunction

Column 1: Cytoband localization of the CNV. Column 2: CNV type, either deletion (DEL, white background row) or duplication (DUP, grey background row). Columns 3 and 4: Genomic coordinates (in Mb) on the GRCh37 reference genome of the start and end position of the merged CNV region that is supported by genome-wide association signals. Columns 5 and 6: Lowest P-values in each CNV region and corresponding odds ratios (OR) (with 95% confidence interval) of the genome-wide CNV meta-analysis in 25,345 individuals with seizures and 492,324 controls. Column 7: GRCh37 coordinates of the credible interval(s) that contained the causal element(s) with 95% confidence. Column 8: Number of neuropsychiatric disorders that also show a significant genome-wide CNV-association in this locus. Column 9: Highest odds ratio for each locus in any of the 23 cross-disorder meta-analyses.

290 kb to 8.9 Mb). All the genome-wide associated deletions found in this study consisted of the loss of one copy, while all duplications consisted of the gain of one copy. Three of the 25 seizure-associated loci (15q11.2-q13.3 dup, 15q13.2-q13.3 del, 16p13.11 del) had previous genome-wide statistical support for an association with epilepsy from our previous study²⁰ that included 40% of the individuals with seizures of this study. All other identified CNVs (22/25, 88%) represent new genome-wide significant loci for seizures, with 10/22 (59%) loci previously implicated in neurological and psychiatric disorders, 6/22 (23%) specifically in epilepsy by studies without genome-wide statistical support, 2/22 (9%) reported in individuals without neurological or psychiatric disorders, and 4/22 (18%) not previously reported regions. We detailed in Table 2 all commonly reported disease phenotypes for the 25 identified seizure-associated loci. Our meta-analysis in seizure disorders was likely not powered enough to identify some of the known CNVs implicated in epilepsy (without genome-wide statistical support) associated with seizures (e.g., 1q21.1 del/dup). Reciprocal CNVs, defined by deletions and duplications associated with seizures involving overlapping genomic segments, were found at 15q11.2, 16p11.2, and 22q11.21. No overlap existed between the seizure-associated CNV regions identified in this study and the most recent SNP-based GWAS study in epilepsy²⁷.

Fine-mapping and candidate genes

Out of the three CNV regions with previous genome-wide statistical support, our fine-mapping approach narrowed down the critical

seizure-relevant region for the known 15q11-q13 duplication to the imprinted promoter/exon 1 region of *SNRPN* (Table 2, Supplementary Fig. 1). The *SNRPN* promoter/exon 1 region was suggested to regulate the imprinting of the critical region for Prader-Willi syndrome^{28,29}. Overexpression of *SNRPN*, corresponding to the seizure-associated duplication of the region, was found to cause abnormal neural development in cultured primary cortical neurons³⁰. Conversely, *SNRPN* knockdown was found in the same study to also cause subtle neuronal abnormalities, in line with reports of short *SNRPN* deletions in Prader-Willi syndrome³¹. For the other two CNV regions with previous genome-wide statistical support, we identified several genes with a brain phenotype in the minimal credible intervals. The 15q13.2-q13.3 deletion credible interval includes the haploinsufficient gene *OTUD7A*, shown to cause abnormal development of cortical dendritic spines and dendrite outgrowth in *Otud7a*^{DEL/+} mice³², and *KLF13*, shown to cause a layer-specific decrease of cortical interneurons in *Klf13*^{DEL/+} mice³³. The 16p13.11 deletion credible interval includes two haploinsufficient genes: *MYH11*, implicated in cerebrovascular disorders^{34,35} that are a risk factor for seizures³⁶, and *MARF1*, involved in cortical neurogenesis³⁷.

Out of the six seizure-associated CNV regions previously implicated in epilepsy without genome-wide statistical support, we mapped the credible intervals of the two seizure-associated deletions at 1p36 to the first and third known critical regions for seizures within the phenotype spectrum of the 1p36 deletion syndrome³⁸. Known disease genes in the credible intervals at 1p36 are *DVLI* (Robinow syndrome³⁹), *TMEM240* (Spinocerebellar ataxia 21⁴⁰), and *SKI* (Shprintzen-Goldberg

Table 2 | Known disease genes in the credible intervals of the seizure-associated CNV regions

Cytoband	CNV type	Best overlapping syndrome	Credible interval containing the causal element/gene with 95% confidence	Brain-related disease genes (high confidence)	PMID
15q11.2-q13.3	DUP	15q11-q13 duplication syndrome (Prader-Willi/Angelman critical region)	15:24750000-25080000	<i>SNRPN</i> overexpression (Neurodevelopmental phenotype)	27430727
				<i>SNRPN</i> deletion (Prader-Willi) if the CNV is gene disrupting	35956251
15q13.2-q13.3	DEL	15q13.3 deletion syndrome	15:31060000-32510000	-	-
16p13.11	DEL	16p13.11 deletion syndrome	16:15420000-16350000	<i>MYH11</i> (Moyamoya-like cerebrovascular disease, cerebral artery aneurysm)	29263223, 27367753
1p36.33	DEL	1p36 deletion syndrome (Seizures critical region 1)	1:910000-1510000	<i>DVL1</i> (Robinow syndrome)	25817016
				<i>TMEM240</i> (Spinocerebellar ataxia 21)	25070513
1p36.33	DEL	1p36 deletion syndrome (Seizures critical region 3)	1:2020000-2490000	<i>SKI</i> (Shprintzen-Goldberg syndrome)	23023332
1q44	DEL	<i>KIF26B</i> deletion	1:245290000-245860000	<i>KIF26B</i> (Pontocerebellar hypoplasia)	30151950
16p12.2	DEL	16p12.1 deletion syndrome	16:21880000-22500000	-	-
16p11.2	DEL	16p11.2 deletion syndrome (BP4-BP5)	16:29560000-30190000	<i>PRRT2</i> (Benign familial infantile seizures)	33746883
				<i>TAOK2</i> (Autism spectrum disorder)	29467497
17q12	DUP	17q12 duplication syndrome	17:34760000-35510000	-	-
			17:35960000-36250000	-	-
2q13	DUP	NPHP1 duplication	2:110770000-111060000	<i>NPHP1</i> duplication (Autism spectrum disorder, global developmental delay)	25126106, 16892302
3q29	DEL	3q29 deletion syndrome	3:195760000-196240000	-	-
			8:400000-610000	-	-
			8:3040000-3780000	-	-
			8:4810000-5470000	-	-
8p23.3-p23.2	DEL	8p23.2-pter deletion syndrome	9:330000-560000	<i>KANK1</i> (Cerebral palsy spastic quadriplegic 2)	16301218
			9:139210000-139590000	-	-
9q34.3	DUP	interstitial 9q34.3 duplication (not encompassing <i>EHMT1</i>)	9:139890000-140120000	<i>GRIN1</i> gain of function (Polymicrogyria)	29365063
			10:133410000-133740000	-	-
10q26.3	DEL	10q26 deletion syndrome	10:134370000-134680000	-	-
			15:22740000-23280000	<i>NIPA1</i> (Spastic paraplegia 6, autosomal dominant)	23897027
15q11.2	DEL	15q11.2 deletion syndrome (BP1-BP2)	15:22740000-23280000	<i>NIPA1</i> (Spastic paraplegia 6, autosomal dominant)	23897027
16p11.2	DUP	16p11.2 duplication syndrome (BP4-BP5)	16:29870000-30190000	-	-
22q11.21	DUP	22q11.21 deletion syndrome (LCRA-LCRD)	22:18990000-19370000	-	-
			22:20200000-21540000	-	-
			22:18990000-19400000	-	-
22q11.21	DEL	22q11.21 deletion syndrome (LCRA-LCRD)	22:19670000-19960000	<i>TBX1</i> (22q11.21 deletion syndrome)	14585638
			22:20650000-21540000	<i>LZTR1</i> (Noonan syndrome)	30368668
2p21-p16.3	DEL	Lynch syndrome locus	2:47500000-47850000	-	-
19p13.3	DUP	non-canonical 19p13.3 duplication	19:1040000-1340000	-	-
15q12-q13.1	DEL	<i>OCA2</i> deletion	15:27930000-28230000	-	-
16p13.3	DUP	non-canonical 16p13.3 duplication	16:600000-890000	<i>STUB1</i> gain of function (early onset dementia syndrome, autosomal dominant ataxia with cognitive decline and autism)	35493319, 32211513
17q21.31	DEL	non-canonical 17q21.31 deletion	17:41080000-41450000	<i>BRCA1</i> (Cancer)	35393462
20q13.33	DUP	novel 20q13.33 duplication	20:62000000-62350000	<i>KCNQ2</i> gain of function (Neurodevelopmental disability, neonatal encephalopathy)	35780567, 28139826
				<i>EEF1A2</i> gain of function (Neurodevelopmental disorders)	32160274

Highlighted are: (1) Darkest grey: three CNV regions with previous genome-wide statistical support for epilepsy (PMID: 32568404), (2) Medium-dark grey: six CNV regions previously implicated in epilepsy without genome-wide statistical support, (3) Medium-light grey: ten CNV regions previously reported in other neurological and psychiatric disorders, and (4) Light grey: four novel CNV regions never reported in neurological or psychiatric disorders. In the second column, DEL and DUP indicate deletions and duplications, respectively. Gene names are formatted in italic.

syndrome⁴¹). In the credible intervals of the remaining CNV regions, we identified the following known disease genes: (i) the haploinsufficient *KIF26B* gene (Pontocerebellar hypoplasia⁴²) as the only gene affected by the 1q44 deletion, and (ii) *PRRT2* (self-limited familial infantile epilepsy, paroxysmal dyskinesia⁴³) and the haploinsufficient *TAOK2* gene (Autism⁴⁴) at the 16p11.2 BP4-BP5 deletion syndrome locus. Of note, single nucleotide variants in *PRRT2* are among the most frequent findings in clinical genetic testing of epilepsy⁴⁵.

Among the ten seizure-associated CNV regions previously reported in other neurological and psychiatric disorders, we identified one credible interval suggesting a different causal gene than previously reported: an interstitial 9q34.3 duplication not encompassing *EHMT1* that is considered as the causal gene based on one out of 22 reported 9q34.3 duplication carrier⁴⁶. The top candidate gene within the credible interval identified by our meta-analysis is *GRIN1*, affected by 9q34.3 duplications in 21 of all reported carriers⁴⁶. *GRIN1* gain of

function variants are known to cause a developmental epileptic encephalopathy, often with polymicrogyria⁴⁷. In contrast, our fine-mapping analysis confirms *TBX1* as the (known) causal gene for the 22q11.21 deletion/DiGeorge syndrome⁴⁸. We also found *LZTR1* (Noonan syndrome⁴⁹) within the credible 22q11.21 deletion intervals. Other known disease genes in the credible intervals of the remaining CNV regions implicated in neurological and psychiatric disorders were: *NPHP1* inside a 2q13 duplication (Autism and global developmental delay^{50,51}), *KANK1* (Cerebral palsy spastic quadriplegic 2⁵²) inside a small 9p24.3 *DOCK8/KANK1* deletion, and *NIPAI* (Autosomal dominant spastic paraplegia 6⁵³) inside the 15q11.2 BPI-BP2 deletion syndrome region.

Finally, we identified four novel CNV regions associated with seizures. Three out of four harbored known disease genes. The credible region of a non-canonical 16p13.3 duplication included *STUB1*. *STUB1* gain of function was reported to cause early onset dementia syndrome⁵⁴ and autosomal dominant ataxia with cognitive decline and autism⁵⁵. The credible region of a non-canonical 17q21.31 deletion included *BRCA1*. *BRCA1* mutations are well-known in cancer⁵⁶, with *BRCA1* as a possible mediator of glioma cell proliferation, migration, and glioma stem cell self-renewal⁵⁷. The credible region of a novel 20q13.33 duplication included *KCNQ2* and *EEF1A2*. *KCNQ2* gain of function is known to cause neurodevelopmental disability and neonatal encephalopathy^{58,59}. *EEF1A2* gain of function was shown to cause neurodevelopmental disorders, including epilepsy and intellectual disability⁶⁰.

Significantly enriched Gene ontology (GO) Biological Processes among all known brain-related disease genes in the credible intervals were: chordate embryonic development (GO:0043009 [<http://amigo.geneontology.org/amigo/search/ontology?q=GO%3A0043009&searchtype=ontology>]), sensory organ morphogenesis (GO:0090596 [<http://amigo.geneontology.org/amigo/search/ontology?q=GO%3A0090596&searchtype=ontology>]), mitotic G2 DNA damage checkpoint signaling (GO:0007095 [<http://amigo.geneontology.org/amigo/search/ontology?q=GO%3A0007095&searchtype=ontology>]), neural tube closure (GO:0001843 [<http://amigo.geneontology.org/amigo/search/ontology?q=GO%3A0001843&searchtype=ontology>]), negative regulation of Ras protein signal transduction (GO:0046580 [<http://amigo.geneontology.org/amigo/search/ontology?q=GO%3A0046580&searchtype=ontology>]), dendrite morphogenesis (GO:0048813 [<http://amigo.geneontology.org/amigo/search/ontology?q=GO%3A0048813&searchtype=ontology>]), and mitotic G2/M transition checkpoint (GO:0044818 [<http://amigo.geneontology.org/amigo/search/ontology?q=GO%3A0044818&searchtype=ontology>])). No GO Biological Process was significantly enriched when considering all genes inside all credible intervals, pointing to likely heterogeneous disease mechanisms of the 25 seizure-associated CNV regions. All credible intervals and known brain-related disease genes are detailed in Table 2, additional candidate genes of lower confidence are detailed in Supplementary Data 1, and all genes inside the credible intervals are detailed in Supplementary Data 2.

Most of the 25 identified risk CNVs are pleiotropic

We performed 23 meta-analyses of epilepsy with 23 other neuropsychiatric disorders (listed in Supplementary Table 2) in an additional 238,161 individuals with neuropsychiatric disorders and 492,324 controls to explore pleiotropy of the 25 identified CNVs. 24 out of 25 seizure-associated CNVs were significantly associated in at least one of the 23 meta-analyses with a neuropsychiatric disorder. The number of neuropsychiatric disorders with which a significant association was found and their greatest odds ratios are reported in Table 1. About two thirds (60%) of all CNVs were highly pleiotropic and showed significant associations with >10 epilepsy/neuropsychiatric disorder meta-analyses. The most frequently co-associated phenotype was

“Neurodevelopmental abnormality” (HP:0012759 [<https://hpo.jax.org/app/browse/term/HP:0012759>]); associated with 36% of all seizure-associated CNVs).

Characterization of the clinical subphenotypes enriched in the carriers of each seizure-associated CNV in epilepsy patients with deep phenotypes

We performed phenome-wide association analyses for each of the 33 credible intervals identified across the 25 CNV regions to characterize the high-resolution clinical manifestations associated with each CNV. This analysis was performed on a subset of the Epi25 Collaborative cohort (Phenomic cohort, Supplementary Table 1) comprising 10,880 individuals with non-acquired epilepsy and deep phenotypic data (the clinical presentation of this cohort of 10,880 individuals and the frequencies of selected common and characteristic epilepsy phenotypes are provided in Supplementary Table 3). In the Phenomic cohort, 562 individuals (5.2%) carried at least one seizure-associated credible interval ($N=498$ / 4.6% carried one credible interval, $N=64$ / 0.6% carried 2–5 credible intervals). The most common credible interval (deletion at 2p21-p16.3) was carried by 114 (1.0%) individuals, and 18 credible intervals were found in at least 0.1% of the cohort (≥ 11 carriers). One CNV was not found (deletion at 9p24.3, containing a single credible interval). Across the 32 detected credible intervals and 1667 annotated HPO concepts, we identified 622 nominally significant associations (two-sided Fisher’s exact test, Supplementary Data 3). Given the large number of associations tested and that HPO annotations describing the same clinical feature at different levels of precision are highly correlated, we applied the minP step-down procedure to aid interpretation⁶¹, yielding 19 associations robust to multiple testing within each genetically defined group (minP-adjusted $P < 0.05$, Table 3, Figs. 2, 3, and Supplementary Fig. 2A–E).

Carriers of deletions at 1p36.33 [0.91–1.51 Mb] ($N=25$, 0.23% of the Phenomic cohort), 1p36.33 [2.02–2.49 Mb] ($N=17$, 0.16%), or 15q12-q13.1 ($N=4$, 0.037%), and carriers of duplications at 15q11.2-q13.3 ($N=46$, 0.42%) were enriched with clinical features suggestive of developmental and epileptic encephalopathies, such as epileptic spasms and tonic seizures, epileptic encephalopathy, and other neurodevelopmental disorders, sudden unexpected death in epilepsy, and morphological abnormalities⁶². Features characterizing genetic generalized epilepsy were associated with deletions at 2p21-p16.3 ($N=114$, 1.05%, generalized tonic-clonic and absence seizures), 15q11.2 ($N=56$, 0.52%, eyelid myoclonia and absence seizures), 16p13.11 ($N=42$, 0.39%, generalized tonic-clonic seizures), 15q13.2-q13.3 ($N=24$, 0.22%, absence seizures) or 22q11.21 [20.65–21.54 Mb] ($N=6$, 0.055%, juvenile myoclonic epilepsy-like features). Duplications at 16p11.2 ($N=8$, 0.074%) were associated with non-epileptic seizures comorbid with epilepsy (OR = 81.5, unadjusted $P = 4.82 \times 10^{-4}$, minP-adjusted $P = 0.0297$), and showed a nonsignificant greater frequency of microcephaly (OR = 31.5, unadjusted $P = 3.62 \times 10^{-2}$, minP-adjusted $P = 0.92$) that replicates the mirror microcephaly/macrocephaly phenotype of the reciprocal 16p11.2 CNVs⁶³.

We interrogated the phenotypic annotations of CNV carriers regarding the candidate genes prioritized in our fine-mapping analysis. *MSH2* was prioritized as the candidate gene for the most common deletion in the Phenomic cohort (2p21-p16.3). Heterozygous loss of function variants of the haploinsufficient gene *MSH2* cause Lynch syndrome 1⁶⁴, and complete knockout of paralog *Msh2* in *Ccm1*^{+/−} mice causes multiple cavernoma through a presumed second hit⁶⁵. We found that carriers had a nonsignificant greater frequency of neoplasms (OR = 2.35, unadjusted $P = 2.49 \times 10^{-2}$, minP-adjusted $P = 1.00$) and cerebral cavernomata (OR = 5.23, unadjusted $P = 6.58 \times 10^{-4}$, minP-adjusted $P = 0.157$) than non-carriers. Carriers of the 1p36.33 [2.02–2.49 Mb] deletion overlapping the gene *SKI* had features (hypotonia, talipes equinovarus, abnormalities of the globe and nose, osteoporosis, global developmental delay, and Chiari malformation)

Table 3 | Significant individual CNV-HPO associations

Locus	CNV type	HPO	Odds ratio [95% CI]	Relative risk	P-value	CNV carriers			CNV non-carriers		
						Raw	Adjusted	Prop	N _{pheno}	N _{tot}	N _{pheno}
15q13.2-q13.3 [31.06–32.51 Mb]	DEL	Generalized non-motor (absence) seizure [HP:0002121]	10.5 [4.25–28.5]	4.18	3.70E–08	1.00E–05	0.667	16	24	1731	10,856
15q13.2-q13.3 [31.06–32.51 Mb]	DEL	Typical absence seizure [HP:0011147]	8.43 [3.48–21.3]	4.1	6.94E–07	1.10E–04	0.583	14	24	1545	10,856
15q13.2-q13.3 [31.06–32.51 Mb]	DEL	EEG with spike-wave complexes [HP:0010850]	7.84 [3.16–21.2]	3.28	1.18E–06	2.00E–04	0.667	16	24	2205	10,856
15q13.2-q13.3 [31.06–32.51 Mb]	DEL	Generalized-onset seizure [HP:0002197]	9.41 [3.15–37.9]	2.4	1.41E–06	2.20E–04	0.833	20	24	3766	10,856
15q13.2-q13.3 [31.06–32.51 Mb]	DEL	EEG with generalized epileptiform discharges [HP:0011198]	6.76 [2.44–23.2]	2.2	1.98E–05	0.00379	0.792	19	24	3905	10,856
15q13.2-q13.3 [31.06–32.51 Mb]	DEL	Bilateral tonic-clonic seizure with focal onset [HP:0007334]	0 [0–0.404]	0	4.07E–04	0.0484	0	0	24	3168	10,856
1p36.33 [0.91–1.51 Mb]	DEL	Hypotonia [HP:0001252]	12.2 [3.95–32]	9.51	3.23E–05	0.00674	0.24	6	25	274	10,855
1p36.33 [0.91–1.51 Mb]	DEL	Epileptic spasm [HP:0011097]	7.47 [2.78–18.4]	5.4	6.85E–05	0.0108	0.32	8	25	643	10,855
1p36.33 [0.91–1.51 Mb]	DEL	Abnormal muscle tone [HP:0003808]	8.65 [2.81–22.7]	6.82	1.97E–04	0.0287	0.24	6	25	382	10,855
1p36.33 [0.91–1.51 Mb]	DEL	Infantile spasms [HP:0012469]	8.34 [2.71–21.9]	6.58	2.39E–04	0.0324	0.24	6	25	396	10,855
1p36.33 [0.91–1.51 Mb]	DEL	Abnormal muscle physiology [HP:0011804]	8.21 [2.67–21.5]	6.48	2.59E–04	0.0339	0.24	6	25	402	10,855
1p36.33 [0.91–1.51 Mb]	DEL	Abnormality of the musculature [HP:0003011]	8.04 [2.61–21.1]	6.35	2.87E–04	0.038	0.24	6	25	410	10,855
1p36.33 [0.91–1.51 Mb]	DEL	Plagiocephaly [HP:0001357]	93.8 [9.48–482]	86.8	3.30E–04	0.045	0.08	2	25	10	10,855
2p21-p16.3 [47.50–47.85 Mb]	DEL	Focal-onset seizure [HP:0007359]	0.463 [0.313–0.681]	0.708	4.79E–05	0.0086	0.456	52	114	6939	10,766
2p21-p16.3 [47.50–47.85 Mb]	DEL	Bilateral tonic-clonic seizure with generalized onset [HP:0025190]	2.3 [1.5–3.46]	1.88	9.09E–05	0.0157	0.325	37	114	1861	10,766
15q12-q13.1 [27.93–28.23 Mb]	DEL	Global developmental delay [HP:0001263]	69.1 [5.55–3540]	18.1	2.80E–04	0.0127	0.75	3	4	451	10,876
15q12-q13.1 [27.93–28.23 Mb]	DEL	Epileptic encephalopathy [HP:0200134]	Inf [4.43–Inf]	7.72	2.83E–04	0.0127	1	4	4	1408	10,876
15q12-q13.1 [27.93–28.23 Mb]	DEL	Encephalopathy [HP:0001298]	Inf [4.41–Inf]	7.69	2.87E–04	0.0129	1	4	4	1414	10,876
16p11.2 [29.87–30.19 Mb]	DUP	Psychogenic non-epileptic seizure [HP:0033052]	81.5 [7.85–471]	61.8	4.82E–04	0.0297	0.25	2	8	44	10,872

In the first column, the genomic band and coordinates of the considered CNV are reported. The CNV type is reported in column 2. In column 3, the HPO term name and identifier are reported. In column 4, the odds ratio with unadjusted two-sided 95% confidence interval is reported. In column 5, the relative risk is given to aid interpretation. In column 6, the unadjusted two-sided *P*-values from Fisher's exact test are reported. In column 7, the minP step-down *P*-value is given, which provides an adjustment for all 1,667 HPO term associations tested within each CNV group, while accounting for the correlation between harmonized HPO annotations (see Online Methods). In column 8, the proportion of CNV carriers annotated with the phenotype is given. In columns 9–10 and 11–12, *N*_{pheno} and *N*_{tot} are the number of individuals annotated with the phenotype and the total number of individuals carrying and not-carrying the CNV, respectively.

concordant to the Shprintzen-Goldberg craniosynostosis syndrome caused by *SKA1*. All 15 individuals with duplication of 9q34.3 had focal-onset seizures that were rarely drug-resistant, without any individual annotated with a neurodevelopmental disorder or polymicrogyria despite the presence of the *GRIN1*, which can cause polymicrogyria when affected by gain-of-function variants⁴⁷. Sixteen of 24 individuals carrying deletions at 15q13.3 [31.06–32.51 Mb] had generalized absence seizures (OR = 10.5, unadjusted *P* = 3.70 × 10^{−8}, minP-adjusted *P* = 1 × 10^{−5}), in line with the primary seizure type reported in carriers of the 15q13.3 deletion⁶⁶. Finding generalized myoclonic seizures in half of the carriers of the 22q11.2 [19.67–19.96 Mb] deletion further confirmed *TBX1*⁶⁷, the known causal gene for the 22q11.21 deletion/DiGeorge syndrome⁴⁸. Features suggestive of juvenile myoclonic

epilepsy were also found among six people carrying deletions overlapping with the second credible interval at 22q11.2 [20.65–21.54 Mb] spanning the Noonan syndrome 10 locus containing in which a single individual was reported with seizures⁴⁹. However, none of these six individuals had annotations beyond seizures and electroencephalography phenotypes that would support a multisystemic syndrome.

Finally, clinicians may want to know the frequency of broad clinical features among carriers of the CNV identified in their patients to improve the interpretation of its clinical relevance and to facilitate genetically stratified prognostication. Therefore, we prioritized 17 common, conceptually broad, and important epilepsy manifestations and comorbidities for visualization, including the co-occurrence of




Fig. 2 | Genotype-first phenomic analysis in 10,880 individuals with detailed clinical data. For each CNV, the proportion of carriers and non-carriers annotated with each HPO concept is plotted. Those above the diagonal were enriched among carriers, and those below were depleted. Odds ratios are represented by dot size. The selected phenotypes labeled were prioritized according to statistical evidence and clinical breadth. Full results for all associations reaching unadjusted $P < 0.05$ are provided in Supplementary Data 3. SUDEP sudden unexpected death in epilepsy, CNS central nervous system, EEG electroencephalogram.

generalized-onset and focal-onset seizures that characterizes the combined generalized and focal epilepsy type⁶² (Fig. 3 and Supplementary Fig. 3A–E). The most common CNV, deletion at 2p21-p16.3, appeared to modestly increase the likelihood of a carrier having generalized epilepsy. However, a few CNVs had a profile dominated by core electroclinical features of generalized (for example, deletions at 15q13.2–15q13.3) or focal epilepsy (duplications at 9q34.3 [139.89–140.12 Mb]), with comorbid features being rare. Conversely, carriers of other CNVs had relatively high frequencies of neurodevelopmental disorders, epileptic spasms, and drug resistance suggestive of developmental and epileptic encephalopathy (deletions at 1p36.33). However, no CNV was found exclusively in people with a particular seizure type, and carriers of some CNVs appeared to have broad clinical features at frequencies indistinguishable from the cohort's baseline (duplications at 19p13.3), suggesting some generic contribution to epilepsy risk across epilepsy types.

Discussion

In this study, we leveraged a substantial increase in sample size to identify novel seizure-associated CNVs when jointly analyzing 26,699 individuals with various types of seizure disorders against 492,324 population controls. We identified 25 novel loci with genome-wide significance for seizure disorders. In addition, all three previously

reported epilepsy-associated loci at genome-wide level maintained genome-wide significance for seizure disorders in our meta-analysis that included the epilepsy cohort from the previous study²⁰. Of the 25 seizure-associated loci, 16 were previously implicated in neurological and psychiatric disorders, including epilepsy. Five were flanked by known segmental duplications (SDs) or low copy number repeats (LCRs). Of note, our fine-mapping analysis confirmed the first and third known critical regions for seizures within the phenotype spectrum of the 1p36 deletion syndrome³⁸, *TBX1* as the (known) causal gene for the 22q11.21 deletion/DiGeorge syndrome⁴⁸, and suggested the *SNRPN* promoter/exon 1 region as the causal element for seizures within the larger BP2-BP3 15q11.2-q13 duplication region. However, our study design did not support the assessment of whether the imprinting status of the duplicated region itself plays an additional role besides the previously suggested role of the *SNRPN* promoter/exon 1 region in regulating the imprinting of the Prader-Willi critical region. Future studies that also include genomic screens of parents will shed light on this open question.

In a high-resolution phenomic analysis in a subset of 10,880 individuals from our cohort with epilepsy (from the Epi25 cohort), we identified 622 suggestive and 19 significant clinical associations informative for epileptologists among CNV carriers. This observation indicates that beyond contributing to the generic risk of seizures, several CNVs contribute to specific epilepsy types. Carriers of some CNVs tended to have features typical of developmental and epileptic encephalopathies with neurodevelopmental and non-seizure phenotypes. Conversely, carriers of others had phenotypes restricted to the core epileptic features of seizures and electroencephalographic abnormalities (both generalized and focal). Interestingly, reciprocal CNVs involving 22q11.21 seemed to produce opposite epilepsy types, with deletion and duplication carriers tending to have generalized and focal epilepsies, respectively. Dose-dependent effects of *KLHL22* on DEPDC5 degradation are a possible explanation⁶⁸. Overall, the high degree of pleiotropy among seizure-associated CNVs implies that these CNVs likely impair neurodevelopmental processes rather generically and contribute to the broad spectrum of neurodevelopmental disorders. According to the oligo-/polygenic inheritance model, CNVs may interact with the genetic background or environmental factors to generate the final disease phenotype. Interaction between CNVs and the polygenic background was recently demonstrated in carriers of the schizophrenia-associated 22q11.2 deletion⁶⁹. Support for an oligogenic-CNV disorder model was also recently published⁷⁰.

Genome-wide genetic screening for pathogenic CNVs is recommended as a first-tier approach for the postnatal evaluation of individuals with intellectual disability, developmental delay, autism spectrum disorder, multiple congenital anomalies, and prenatal evaluation of fetuses with structural anomalies observed by ultrasound^{71–73}. It has previously been shown that CNVs confer significant risk towards epilepsy^{1,2,4–8,10,13,74}, particularly for individuals with comorbid neurodevelopmental disorders such as intellectual disability^{21,74–76}. In contrast to single nucleotide polymorphism SNP GWAS for epilepsy or seizures, where the risk of identified variants is small ($OR < 2$)^{77,78}, the effect sizes of the 25 CNVs identified in this study are large (median $OR = 11$, range 2–53). Our high-resolution phenomic analysis of 10,880 individuals with epilepsy grouped by CNV carrier status illustrates the seizures, EEG and brain imaging findings, and neurodevelopmental and other co-morbidities associated with each CNV. This genotype-first approach complements the traditional single-phenotype, case-control paradigm by taking a simultaneous phenome-wide perspective in individuals deeply phenotyped according to standardized protocols before CNV discovery or genetic association tests. We found phenotypic evidence supporting associations between CNVs, broad markers of epilepsy types, and fine-grained phenotypes. The high-resolution phenotype associations that an epileptologist can recognize derived from the HPO phenotype association analysis and




Fig. 3 | Summary clinical signatures of CNVs in a deeply phenotyped epilepsy cohort. The percentage of carriers of the CNV with each broad phenotype is shown by the height of bars arranged on a polar axis, with two-sided 95% confidence interval error bars for these percentages derived from the binomial distribution using *stats::binom.test()*. For reference, dots indicate the percentage of the entire Phenomic cohort of 10,880 people with each broad phenotype (representing the prior probability of a person having the phenotype without genetic stratification). The binomial distribution two-sided 95% confidence intervals for a cohort size of 10,880 are no wider than 1.9% (not shown for clarity). “Craniofacial or skeletal dysmorphism” includes individuals with either “Abnormality of the head [HP:

0000234]” (which excludes isolated brain structural abnormalities) or “Abnormal skeletal morphology [HP:0011842]”. “Motor, movement or muscular disorder” includes individuals with any of “Abnormal central motor function [HP:0011442]”, “Abnormality of movement [HP:0100022]” or “Abnormality of the musculature [HP:0003011]”, but not “Motor delay [HP:0001270]”, which is included in “Neurodevelopmental abnormality”. While “Neurodevelopmental abnormality” includes those with “Intellectual disability”, the latter is shown additionally as it is a neurodevelopmental outcome with particularly important socioeconomically important consequences. EEG electroencephalogram. Further CNV profiles are shown in Supplementary Fig. 2.

disease risk estimates from the meta-analysis for each CNV can enhance the interpretation of clinical relevance and pathogenicity following the American College for Genetics and Genomics Copy Number variant interpretation guidelines²⁴.

Our study has several limitations. First, many of the patients with seizures included in this study have comorbid neurological and psychiatric disorders. Therefore, some of the identified CNV loci may be associated with other clinical phenotypes present in a high percentage of all cases. Second, we did not detect robust associations with two important outcomes in our HPO analysis, refractory drug response and sudden unexpected death. Sudden unexpected death in epilepsy is poorly suited to cross-sectional studies: it was annotated to only 4 of 10,880 individuals, far fewer cases than expected to occur with follow-up of this cohort of individuals requiring tertiary center care⁷⁹. This emphasizes the open-world interpretation required for our results: in any study that is cross-sectional and of a disorder that has inherently variable phenotyping depth (epilepsy presentations can often be classified only incompletely)¹⁶², and which is characterized by some phenotypes that are age-dependent (such as some seizure types, autism, and intellectual disability), one should rarely assume that the absence of an annotation can be interpreted as the absence of that phenotype over the lifetime of the carrier. Thus, the proportion of individuals annotated with a phenotype is likely lower than the actual proportion manifesting it over their lifetimes⁸⁰. Third, in contrast to conventional SNP-based GWASs, CNV-GWASs have major challenges in identifying the causal gene(s) impacted by the CNV. Among the 25 identified CNVs, deletions ranged from 230 kb to 5 Mb and duplications from 290 kb to 9 Mb, affecting 14.2 genes on average. CNV breakpoints in the current study are estimated from genotyped SNPs around the actual breakpoint. These breakpoint estimates are limited by the resolution of the genotyping platform used to call the CNVs. In fact, microarrays have many technical limitations, such as poor breakpoint resolution and limited sensitivity for small CNVs⁸¹. Newer technologies like whole-genome sequencing (WGS) will enable the assessment of a more comprehensive array of rare variants, including balanced rearrangements, small (exonic) CNVs⁸², short tandem repeats, and other structural variants⁸³. However, some genomic regions harbor complex deletion/duplication/inversion rearrangements (e.g., 22q11.21⁸⁴, 15q11.2⁸⁵) that can even show population stratification (e.g., 16p11.2⁸⁶). More accurate and complete (pangenome) references will be needed to determine the exact breakpoints of such complex rearrangements^{87,88}, even in the case of sequencing-based CNVs discovery. Lastly, we performed joint epilepsy/seizures and cross-disorder meta-analyses in individuals with minimal clinical information. Future studies with access to rich clinical metadata, such as electronic health records, will likely identify additional seizure-associated CNVs. It is important to consider the inclusion criteria for this cohort and the definition of cases and controls when interpreting associations and their relevance to a patient. Our phenomic analysis cohort was performed using the years 1–3 data of the Epi25 Collaborative, predominantly recruited from academic epilepsy centers and of European ancestry (92.9%, see Online Methods). Additionally, we screened cases to exclude those with brain trauma, meningitis, or encephalitis. Thus, our clinical associations should be considered most valid in individuals of European ancestry with likely genetic or unexplained epilepsies attending specialist epilepsy centers. Future data analyses from subsequent years of Epi25 will provide data more applicable to other populations.

Large-scale collaborations that enable the aggregation of massive datasets have greatly advanced epilepsy and the discovery of genetic factors through GWASs. Here, we have extended this framework to CNV discovery by meta-analyzing epilepsy and seizure disorders, followed by additional meta-analyses in neuropsychiatric disorders and traits to explore pleiotropy. We also identified fine-grained genotype-phenotype associations and clinical profiles for each CNV. Our results

will help refine promising candidate CNVs associated with specific epilepsy types and extend their clinical value. We are confident that applying this framework to even larger datasets has the potential to advance the discovery of all clinically relevant risk loci, ultra-rare high-risk CNVs missed by this study, and the underlying genes or functional elements.

Methods

Study cohorts

Each center's ethics committees/institutional review boards approved data collection and use. For the Epi25 cohort, patients or their legal guardians provided signed informed consent/assent according to local IRB requirements; as samples had been collected over 20 years in some centers, forms reflected standards at the time of collection. For Epi25 Consortium samples collected after 25th January 2015, forms required specific language according to the NIH Genomic Data Sharing Policy.

Individuals with clinically defined epilepsy - Epi25 Collaborative

Individuals with ILAE-defined epilepsy ($N=16,109$) were collected through the Epi25 Collaborative. The epilepsy diagnosis was performed according to clinical criteria (clinical interview, neurological examination, EEG, imaging data), following International League Against Epilepsy (ILAE) classifications⁸⁹. All cohorts are detailed in Supplementary Table 1. All individuals of the Epi25 Collaborative cohort were selected to be of principal component analysis (PCA)-defined European ancestry. Ancestry-matched population controls ($N=8545$) for the Epi25 arm of the study were recruited through (1) the Epi25 Collaborative, (2) a Broad Institute project on inflammatory bowel disease without reported epilepsy (part of the IBD Genetics Collaborative, IBDGC), (3) healthy individuals from the Genetics of Personality Collaborative (GPC), and (4) the THL Institute for Health and Welfare (subsample of the FINRISK study)⁹⁰. Genotyping for all cases and controls was performed on the same genotyping array (Illumina Infinium Global Screening Array, GSA-MD v1.0) and at the same center (Broad Institute) as the epilepsy cases. For a detailed description, see ref. 20.

CNV calling and quality control - Epi25 Collaborative

We restricted our analysis to only autosomal CNVs due to a higher quality of calls and followed the quality control (QC) pipeline developed in our previous study²⁰. In detail, QC was performed in two major steps (1) pre-CNV calling QC and (2) post-CNV calling QC. For pre-CNV calling QC, we excluded samples with a call rate <0.96 or discordant sex status. To select individuals of European ancestry, we filtered autosomal SNPs for low genotyping rate (<0.98), a high difference in the SNP minor allele frequency between cases and controls (>0.05), deviation from Hardy-Weinberg equilibrium (HWE) with $P \leq 0.001$, and pruned the remaining SNPs for linkage disequilibrium ($-r^2$ pairwise 200 100 0.2) using PLINK v1.9⁹¹. We then performed a principal component analysis (PCA) of the Epi25 cases and controls using PLINK v1.9⁹¹ and GCTA⁹². European individuals were defined as individuals clustering with the 1000 Genomes Project⁹³ European samples. We created GC wave-adjusted LRR (Log-R ratio) intensity files for all samples using PennCNV, generated a custom population B-allele frequency file, and employed PennCNV's CNV calling algorithms^{2,94} to detect CNVs in our dataset. The post-CNV calling QC included the following steps: (1) CNV calls of the same type (deletion or duplication) were merged if the number of SNP/intensity markers between them was $<20\%$ of the total number when both segments were combined; (2) CNVs supported by <20 markers, <20 kb long, and with a SNP density <0.0001 were excluded from subsequent analyses; (3) CNVs that overlapped other CNVs in $\geq 1\%$ of all samples within the Epi25 dataset were excluded to remove potential platform-specific artifacts, (4) CNVs with $>50\%$ overlap with telomeric, centromeric, and

immunoglobulin regions of the hg19 reference assembly were excluded; (5) CNVs with $\geq 50\%$ overlap with reported common CNVs (allele frequency $>1\%$) in two independent CNV reference catalogs (DGV Gold Standard Dataset⁹⁵; DECIPHER Population Copy-Number Variation Frequencies⁹⁶) were excluded. Finally, the probe-level intensity plots of all CNVs supporting the seizure-associated regions (Table 1) were visually inspected to exclude any remaining artifacts. The DGV Gold Standard and DECIPHER Population frequencies of the remaining CNVs are given in Supplementary Table 4.

Individuals with seizures or neuropsychiatric phenotypes - neuropsychiatric disorders cohort

A large CNV dataset from individuals with a range of neuropsychiatric disorders (including seizure disorders) was aggregated from 17 different sources by Collins et al.⁹⁷. The contributors of each cohort provided the specific clinical phenotypes. The aggregated individuals were grouped into 54 partially overlapping disease phenotypes standardized through the Human Phenome Ontology⁹⁸. The 54 different phenotypes of Collins et al.⁹⁷ were obtained through a recursive hierarchical clustering that defined a minimal set of nonredundant primary phenotypes, each including a minimum of >300 samples in at least three independent cohorts, >3000 samples in total across all cohorts, and had less than 80% sample overlap with any other phenotype. Of the 54 phenotypes, we only selected neurological and psychiatric HPO-based phenotypes ($N=23$, excluding Seizures, Supplementary Table 2). The architecture of these HPO-based phenotypes allows the identification of associations at different levels, from broad to narrow phenotypes, providing the opportunity to distill between pleiotropic and specific associations. This data set also included the Epi25 cohort from our previous CNV GWAS study²⁰. This previous (outdated) Epi25 cohort was excluded from the neuropsychiatric cohort for cross-disorder meta-analyses in the present work. All the considered cohorts are listed in Supplementary Table 1. This aggregated CNV dataset comprised 248,751 individuals affected by at least one of 24 neuropsychiatric disorders, including 10,590 individuals with seizures and 483,779 population controls.

Quality control - neuropsychiatric disorders cohort

The CNV harmonization procedure for the Neuropsychiatric cohort is described in the Supplementary Materials of Collins et al.⁹⁷ and included following steps: (1) CNV calls of the same type (deletion or duplication) were merged if their breakpoints were within $\pm 25\%$ of the size of their corresponding original CNV calls to avoid over-segmentation of large CNV calls; (2) CNVs not mapped to autosomes from the primary hg19 assembly were excluded; (3) Only CNVs between ≥ 100 kb and ≤ 20 Mb in size were considered; (4) CNVs that matched reported common CNVs (allele frequency $>1\%$) in three independent CNV reference catalogs derived from genome sequencing (Abel et al.⁹⁹; Collins et al.¹⁰⁰; Sudmant et al.⁸¹) were excluded; (5) CNVs that overlapped other CNVs in $\geq 1\%$ of samples within the same dataset or in any of the other array CNV datasets were excluded to remove potential platform specific artifacts; (6) We excluded all CNVs with $\geq 30\%$ overlap with somatic hypermutable sites, segmental duplications, simple/low-complexity/satellite repeats, or N-masked bases of the hg19 reference assembly.

Genome-wide association analysis

We performed segment-based CNV burden analyses to identify genomic regions with a significant increase of CNVs in epilepsy cases compared to controls, separated by CNV type (deletion or duplication). We adopted a sliding window approach as introduced by Collins et al.²⁶. The sliding windows model allowed association testing of all autosomes through 267,237 sliding windows characterized by a window size of 200 kb and a step size of 10 kb, corresponding to 13,339.6 non-overlapping windows. Each of these windows was required to have

a low overlap with hypermutable sites, segmental duplications, simple/low-complexity/satellite repeats, and N-masked regions ($>30\%$). For each of the genomic regions, we counted the number of overlapping CNVs separately for cases and controls for each CNV type (deletion or duplication). We required an overlap between the CNV and the genomic window of $\geq 10\%$ to reveal the potential burden of small deletions or duplications (size ≥ 20 kb). We used the one-sided Fisher test as the test statistic for the CNVs collapsed for each segment. Cases/control CNV counts and the Fisher tests were performed using the CNV docker available at <https://hub.docker.com/r/talkowski/rcnv> and custom python (version 3.7.9) and R (version 3.6.1) scripts. The same procedure was applied to the cohorts of the neuropsychiatric disorder dataset, as detailed in Collins et al.²⁶.

Meta-analysis and fine-mapping

Fixed-effects meta-analyses were performed using the *metafor* R (version 3.6.1) package with an empirical continuity correction¹⁰¹ and a saddlepoint re-approximation of the null distribution used for inference. The meta-analysis procedure is detailed in Collins et al.²⁶. We meta-analyzed the effect sizes from 7 GWAS derived from the 17 cohorts of the neuropsychiatric disorder dataset with each segment-based P -value of the Epi25 dataset. The threshold for genome-wide significance was set to $\alpha = 3.74 \times 10^{-6}$ after Bonferroni correction for multiples testing corresponding to the number of independent, non-overlapping 200 kb windows, calculated by merging all overlapping windows and dividing the sum of their sizes by 200 kb (effective $N=13,339.6$ independent windows; $P=3.74 \times 10^{-6}$). To account for possible cohort-specific biases, we expected each segment to fulfill the following additional criteria: (1) at least two cohorts featuring nominal significant P -values ($P < 0.05$) for the given segment, and (2) a meta-analysis $P < 0.05$ after excluding the single most significant cohort. We then used a Bayesian algorithm¹⁰² to identify the minimal credible interval(s) that contained the causal element(s) or genes with 95% confidence, as in Collins et al.⁹⁷. Finally, we explored the known biological function of all genes within the credible intervals and performed pathway analyses using Enrichr^{103,104} (<https://maayanlab.cloud/Enrichr/>). All resources used to investigate the knowledge basis of all seizure-associated CNV regions are described in Supplementary Table 5.

Detailed HPO characterization of Epi25 participants

To identify phenotypic associations with each of the CNVs within a cohort of individuals with epilepsy, we translated clinical data from years 1–3 of the deeply phenotyped Epi25 Collaborative international cohort into Human Phenotype Ontology (HPO, version released 2022-02-14) concepts, following our optimization of the HPO for epilepsy phenotypes¹⁰⁵. We selected only individuals with CNV data and sufficiently detailed clinical data (as of 2022-01-25) to confirm the presence of seizures or epileptic encephalopathy with continuous spike-and-wave in sleep (EE-SWAS, an epilepsy syndrome in which overt clinical seizures may not always be observed). Categorical clinical data were mapped to HPO concepts using a data dictionary. Free text data were annotated with HPO terms manually (D.L.S. under the supervision of I.H. and R.H.T.)²⁵. Quantitative data related to the gestational age, weight, and head circumference at birth were categorized to match HPO definitions using sex-stratified distributions from the INTERGROWTH-21st Project using the R *growthstandards* package (version 0.1.5)¹⁰⁶.

We inferred all HPO concepts applicable to each individual from those translated from the clinical data by propagation, following the *is_a* relationships between HPO concepts as previously described¹⁰⁷, using the R *ontologyIndex* package (version 2.7)¹⁰⁸. We excluded HPO terms that carried no information in the context of this cohort (those that were annotated ubiquitously) and modified the relationships of others, tailoring them to this analysis (Supplementary Table 6).

Phenotypes were annotated as being explicitly present or not, without annotating any phenotypes as being explicitly absent. Taking this open-world perspective is conservative, meaning that the proportion of individuals in a group annotated with a particular phenotype should be considered a lower limit while still allowing statistical testing of phenotypic associations and mitigating the risk of explicitly annotating a phenotype as absent when it was present but not recorded or the individual will manifest the phenotype at some point in the future⁸⁰.

After excluding individuals with markers of acquired epilepsy that are unlikely to be part of the phenotype, such as significant brain trauma, encephalitis, or meningitis, 10,880 individuals from the genomic analysis had adequate phenotypic data available for analysis. Of these, 10,106 individuals are of European ancestry, 602 of East Asian ancestry, and 172 of African ancestry, according to PCA analysis. After propagation to infer generic phenotypic descriptors from specific ones, this cohort had 214,203 informative annotations (median = 17 per individual, range = 1–128), spanning a repertoire of 1667 phenotypic concepts. The frequency of annotation of all 1667 phenotypes is available in Supplementary Data 4.

Phenome-wide association analysis of CNVs

All association analyses and phenomic visualizations were performed in R. Associations between CNVs, and HPO concepts were calculated using the Fisher's exact test (function *fisher.test* from the *stats* package). The tested phenotypes were all those 1667 HPO terms translated from clinical data that were informative (not ubiquitous) and are detailed in Supplementary Table 3. While this was a descriptive analysis, given a large number of tests performed ((29 groups of multiple individuals + 2 groups of a single individual) × 1667 HPO concepts = 51,677), we sought to aid identification of the most robust associations. Bonferroni's single step and Holm's step-down adjustments are overly conservative given the dependence structure of propagated HPO annotations. For example, after full harmonization, annotations of Typical absence seizure [HP:0011147], Generalized non-motor (absence) seizure [HP:0002121], and Generalized-onset seizure [HP:0002197] will be highly correlated because an individual cannot have the first without the second or the second without the last as a result of there *is_a* relationships in the HPO. Therefore we applied the minP step-down procedure, which uses a permutation-based approach to control the family-wise error rate⁶¹. We selected 100,000 randomly generated groups of individuals from the Epi25 phenomic analysis cohort of size *N*, where *N* is the number of carriers of each CNV. Then for each of these groups, we calculated the two-sided Fisher's exact test *P*-values for every one of the 1667 HPO concepts. We used the *adj_Wstep* function from the *NRejections* package (version 1.2.0) in R to perform the step-down procedure. This generated *P*-values corrected for the correlation-adjusted number of tested HPO annotations. We did not adjust *P*-values across CNVs because we were interested only in identifying those associations that were most robust in this descriptive analysis.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All genome-wide CNV association summary statistics are available at Zenodo (<https://zenodo.org/record/7939126#.ZGK7yi-B29Y> with <https://doi.org/10.5281/zenodo.7939126>). Individual-level CNV data for epilepsy patients are available from the Epi25 Consortium (<http://epi-25.org/>) upon signing the Epi25 charter (See Epi25 page <http://epi-25.org/>) and submission and acceptance of a full research proposal. Furthermore, raw data is deposited at dbGAP https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001551.v1.pl. All HPO-based phenome-wide summary statistics are available in

Supplementary Data 3 of this manuscript. Fine-mapping results are available in Supplementary Data 1 and 2 of this manuscript. The CNV data of the Neuropsychiatric cohort are described in the Supplementary Materials of Collins et al.⁹⁷. They can be accessed from existing publications, public resources, or, upon request, from the authors of Collins et al.⁹⁷ (see “Key resources table” and Table S2 in Collins et al.⁹⁷). The CNV data reported by GeneDx and Indiana University clinical testing sites were not consented for public release. All datasets used in this study are detailed in Supplementary Table 1 of our manuscript.

Code availability

The code for the association and meta analysis is available and have been deposited at Zenodo (<https://github.com/talkowski-lab/rCNV2/tree/v1.0>, with <https://doi.org/10.5281/zenodo.6647918>). Also, we provided a Docker image hosted on DockerHub (<https://hub.docker.com/r/talkowski/rcnv>) and Google Container Registry (<https://gcr.io/gnomad-wgs-v2-sv/rcnv>), which provides a controlled container environment containing all dependencies necessary to execute the code identically as presented in this study.

References

1. Fisher, R. S. et al. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia* **55**, 475–482 (2014).
2. Fisher, R. S. et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia* **58**, 522–530 (2017).
3. Berg, A. T., Jallon, P. & Preux, P. M. The epidemiology of seizure disorders in infancy and childhood: definitions and classifications. *Handb. Clin. Neurol.* **111**, 391–398 (2013).
4. Amiet, C. et al. Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. *Biol. Psychiatry* **64**, 577–582 (2008).
5. Sisodiya, S. M. & Mefford, H. C. Genetic contribution to common epilepsies. *Curr. Opin. Neurol.* **24**, 140–145 (2011).
6. Lal, D. et al. Burden analysis of rare microdeletions suggests a strong impact of neurodevelopmental genes in genetic generalised epilepsies. *PLoS Genet.* **11**, e1005226 (2015).
7. Heinzen, E. L. et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. *Am. J. Hum. Genet.* **86**, 707–718 (2010).
8. Addis, L. et al. Analysis of rare copy number variation in absence epilepsies. *Neurol. Genet.* **2**, e56 (2016).
9. Mefford, H. C. CNVs in Epilepsy. *Curr. Genet. Med. Rep.* **2**, 162–167 (2014).
10. Olson, H. et al. Copy number variation plays an important role in clinical epilepsy. *Ann. Neurol.* **75**, 943–958 (2014).
11. Dibbens, L. M. et al. Familial and sporadic 15q13.3 microdeletions in idiopathic generalized epilepsy: precedent for disorders with complex inheritance. *Hum. Mol. Genet.* **18**, 3626–3631 (2009).
12. de Kovel, C. G. F. et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. *Brain J. Neurol.* **133**, 23–32 (2010).
13. Pérez-Palma, E. et al. Heterogeneous contribution of microdeletions in the development of common generalised and focal epilepsies. *J. Med. Genet.* **54**, 598–606 (2017).
14. Helbig, I. et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. *Nat. Genet.* **41**, 160–162 (2009).
15. Fortin, O. et al. Copy number variation in genetic epilepsy with febrile seizures plus. *Eur. J. Paediatr. Neurol.* **27**, 111–115 (2020).
16. Takumi, T. & Tamada, K. CNV biology in neurodevelopmental disorders. *Curr. Opin. Neurobiol.* **48**, 183–192 (2018).
17. Sanders, S. J. et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. *Neuron* **87**, 1215–1233 (2015).

18. Leppa, V. M. et al. Rare inherited and de novo CNVs reveal complex contributions to ASD risk in multiplex families. *Am. J. Hum. Genet.* **99**, 540–554 (2016).
19. Pinto, D. et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am. J. Hum. Genet.* **94**, 677–694 (2014).
20. Niestroj, L.-M. et al. Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17458 subjects. *Brain J. Neurol.* **143**, 2106–2118 (2020).
21. Coppola, A. et al. Diagnostic implications of genetic copy number variation in epilepsy plus. *Epilepsia* **60**, 689–706 (2019).
22. Sheidley, B. R. et al. Genetic testing for the epilepsies: a systematic review. *Epilepsia* **63**, 375–387 (2022).
23. Okur, V. et al. Clinical and genomic characterization of 8p cytogenomic disorders. *Genet. Med.* **23**, 2342–2351 (2021).
24. Riggs, E. R. et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genet. Med.* **22**, 245–257 (2020).
25. Köhler, S. et al. The human phenotype ontology in 2021. *Nucleic Acids Res.* **49**, D1207–D1217 (2021).
26. Collins, R. L. et al. A cross-disorder dosage sensitivity map of the human genome. <https://doi.org/10.1101/2021.01.26.21250098> (2021).
27. International League Against Epilepsy Consortium on Complex Epilepsies, Berkovic, S. F., Cavalleri, G. L. & Koeleman, B. P. Genome-wide meta-analysis of over 29,000 people with epilepsy reveals 26 loci and subtype-specific genetic architecture. <https://doi.org/10.1101/2022.06.08.22276120> (2022).
28. Bielinska, B. et al. De novo deletions of SNRPN exon 1 in early human and mouse embryos result in a paternal to maternal imprint switch. *Nat. Genet.* **25**, 74–78 (2000).
29. Ohta, T. et al. Imprinting-mutation mechanisms in Prader-Willi syndrome. *Am. J. Hum. Genet.* **64**, 397–413 (1999).
30. Li, H. et al. The autism-related gene SNRPN regulates cortical and spine development via controlling nuclear receptor Nr4a1. *Sci. Rep.* **6**, 29878 (2016).
31. Grootjen, L. N., Juriaans, A. F., Kerkhof, G. F. & Hokken-Koelega, A. C. S. Atypical 15q11.2-q13 deletions and the Prader-Willi Phenotype. *J. Clin. Med.* **11**, 4636 (2022).
32. Uddin, M. et al. OTUD7A regulates neurodevelopmental phenotypes in the 15q13.3 Microdeletion Syndrome. *Am. J. Hum. Genet.* **102**, 278–295 (2018).
33. Malwade, S. et al. Identification of vulnerable interneuron subtypes in 15q13.3 microdeletion syndrome using single-cell transcriptomics. *Biol. Psychiatry* **91**, 727–739 (2022).
34. Ravindra, V. M. et al. Rapid de novo aneurysm formation after clipping of a ruptured middle cerebral artery aneurysm in an infant with an MYH11 mutation. *J. Neurosurg. Pediatr.* **18**, 463–470 (2016).
35. Keylock, A. et al. Moyamoya-like cerebrovascular disease in a child with a novel mutation in myosin heavy chain 11. *Neurology* **90**, 136–138 (2018).
36. Steinlin, M. Cerebrovascular disorders in childhood. *Handb. Clin. Neurol.* **112**, 1053–1064 (2013).
37. Kanemitsu, Y. et al. The RNA-binding protein MARF1 promotes cortical neurogenesis through its RNase activity domain. *Sci. Rep.* **7**, 1155 (2017).
38. Jordan, V. K., Zaveri, H. P. & Scott, D. A. 1p36 deletion syndrome: an update. *Appl. Clin. Genet.* **8**, 189–200 (2015).
39. White, J. et al. DVL1 frameshift mutations clustering in the penultimate exon cause autosomal-dominant Robinow syndrome. *Am. J. Hum. Genet.* **96**, 612–622 (2015).
40. Delplanque, J. et al. TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. *Brain J. Neurol.* **137**, 2657–2663 (2014).
41. Doyle, A. J. et al. Mutations in the TGF- β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. *Nat. Genet.* **44**, 1249–1254 (2012).
42. Wojcik, M. H. et al. De novo variant in KIF26B is associated with pontocerebellar hypoplasia with infantile spinal muscular atrophy. *Am. J. Med. Genet. A.* **176**, 2623–2629 (2018).
43. Landolfi, A., Barone, P. & Erro, R. The spectrum of PRRT2-associated disorders: update on clinical features and pathophysiology. *Front. Neurol.* **12**, 629747 (2021).
44. Richter, M. et al. Altered TAOK2 activity causes autism-related neurodevelopmental and cognitive abnormalities through RhoA signaling. *Mol. Psychiatry* **24**, 1329–1350 (2019).
45. Lindy, A. S. et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. *Epilepsia* **59**, 1062–1071 (2018).
46. Bonati, M. T. et al. 9q34.3 microduplications lead to neurodevelopmental disorders through EHMT1 overexpression. *Neurogenetics* **20**, 145–154 (2019).
47. Fry, A. E. et al. De novo mutations in GRIN1 cause extensive bilateral polymicrogyria. *Brain* **141**, 698–712 (2018).
48. Yagi, H. et al. Role of TBX1 in human del22q11.2 syndrome. *Lancet Lond. Engl.* **362**, 1366–1373 (2003).
49. Umeki, I. et al. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes. *Hum. Genet.* **138**, 21–35 (2019).
50. Baris, H. et al. Identification of a novel polymorphism-the duplication of the NPHP1 (nephronophthisis 1) gene. *Am. J. Med. Genet. A.* **140A**, 1876–1879 (2006).
51. Yasuda, Y. et al. Duplication of the NPHP1 gene in patients with autism spectrum disorder and normal intellectual ability: a case series. *Ann. Gen. Psychiatry* **13**, 22 (2014).
52. Lerer, I. et al. Deletion of the ANKRD15 gene at 9p24.3 causes parent-of-origin-dependent inheritance of familial cerebral palsy. *Hum. Mol. Genet.* **14**, 3911–3920 (2005).
53. Fink, J. K. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. *Acta Neuropathol.* **126**, 307–328 (2013).
54. Reis, M. C. et al. A severe dementia syndrome caused by intron retention and cryptic splice site activation in STUB1 and exacerbated by TBP repeat expansions. *Front. Mol. Neurosci.* **15**, 878236 (2022).
55. Chen, D.-H. et al. Heterozygous STUB1 missense variants cause ataxia, cognitive decline, and STUB1 mislocalization. *Neurol. Genet.* **6**, 1–13 (2020).
56. Garber, H. R. et al. Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. *NPJ Breast Cancer* **8**, 46 (2022).
57. Wang, B. et al. BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF- β /PI3K/AKT/mTOR signalling pathway. *Cell. Oncol. Dordr.* **43**, 223–235 (2020).
58. Mulkey, S. B. et al. Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain-of-function variants R201C and R201H. *Epilepsia* **58**, 436–445 (2017).
59. Miceli, F. et al. KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism. *EBio-Medicine* **81**, 104130 (2022).
60. Davies, F. C. J. et al. Recapitulation of the EEF1A2 D252H neurodevelopmental disorder-causing missense mutation in mice reveals a toxic gain of function. *Hum. Mol. Genet.* **29**, 1592–1606 (2020).

61. Westfall, P. H. & Wolfinger, R. D. Multiple tests with discrete distributions. *Am. Stat.* **51**, 3–8 (1997).
62. Scheffer, I. E. et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. *Epilepsia* **58**, 512–521 (2017).
63. Golzio, C. et al. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. *Nature* **485**, 363–367 (2012).
64. Barrow, E. et al. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. *Clin. Genet.* **74**, 233–242 (2008).
65. McDonald, D. A. et al. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. *Hum. Mol. Genet.* **20**, 211–222 (2011).
66. Whitney, R. et al. The spectrum of epilepsy in children with 15q13.3 microdeletion syndrome. *Seizure* **92**, 221–229 (2021).
67. Strehlow, V. et al. Generalized epilepsy and myoclonic seizures in 22q11.2 deletion syndrome. *Mol. Syndromol.* **7**, 239–246 (2016).
68. Chen, J. et al. KLHL22 activates amino-acid-dependent mTORC1 signalling to promote tumorigenesis and ageing. *Nature* **557**, 585–589 (2018).
69. Cleynen, I. et al. Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. *Mol. Psychiatry* **26**, 4496–4510 (2021).
70. Stefanski, A. et al. Identification and quantification of oligogenic loss-of-function disorders. *Genet. Med.* **24**, 729–735 (2022).
71. Manning, M. & Hudgins, L. Professional Practice and Guidelines Committee. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet. Med.* **12**, 742–745 (2010).
72. Miller, D. T. et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am. J. Hum. Genet.* **86**, 749–764 (2010).
73. Stosic, M., Levy, B. & Wapner, R. The use of chromosomal microarray analysis in prenatal diagnosis. *Obstet. Gynecol. Clin. North Am.* **45**, 55–68 (2018).
74. Mefford, H. C. et al. Rare copy number variants are an important cause of epileptic encephalopathies. *Ann. Neurol.* **70**, 974–985 (2011).
75. Mullen, S. A. et al. Copy number variants are frequent in genetic generalized epilepsy with intellectual disability. *Neurology* **81**, 1507–1514 (2013).
76. Reinthaler, E. M. et al. 16p11.2 600 kb Duplications confer risk for typical and atypical Rolandic epilepsy. *Hum. Mol. Genet.* **23**, 6069–6080 (2014).
77. Skotte, L. et al. Genome-wide association study of febrile seizures implicates fever response and neuronal excitability genes. *Brain J. Neurol.* **145**, 555–568 (2022).
78. International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. *Nat. Commun.* **9**, 5269 (2018).
79. Harden, C. et al. Practice Guideline Summary: Sudden Unexpected Death in Epilepsy Incidence Rates and Risk Factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Epilepsy Curr.* **17**, 180–187 (2017).
80. Lewis-Smith, D. et al. Computational analysis of neurodevelopmental phenotypes: Harmonization empowers clinical discovery. *Hum. Mutat.* <https://doi.org/10.1002/humu.24389> (2022).
81. Sudmant, P. H. et al. An integrated map of structural variation in 2,504 human genomes. *Nature* **526**, 75–81 (2015).
82. Brandler, W. M. et al. Frequency and complexity of de novo structural mutation in autism. *Am. J. Hum. Genet.* **98**, 667–679 (2016).
83. Gymrek, M. et al. Abundant contribution of short tandem repeats to gene expression variation in humans. *Nat. Genet.* **48**, 22–29 (2016).
84. Vervoort, L. & Vermeesch, J. R. The 22q11.2 low copy repeats. *Genes* **13**, 2101 (2022).
85. Gimelli, G. et al. Genomic inversions of human chromosome 15q11-q13 in mothers of Angelman syndrome patients with class II (BP2/3) deletions. *Hum. Mol. Genet.* **12**, 849–858 (2003).
86. González, J. R. et al. A common 16p11.2 inversion underlies the joint susceptibility to asthma and obesity. *Am. J. Hum. Genet.* **94**, 361–372 (2014).
87. Porubsky, D. et al. Inversion polymorphism in a complete human genome assembly. <https://doi.org/10.1101/2022.10.06.511148> (2022).
88. Liao, W.-W. et al. A Draft Human Pangenome Reference. <https://doi.org/10.1101/2022.07.09.499321> (2022).
89. Berg, A. T. et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia* **51**, 676–685 (2010).
90. Borodulin, K. et al. Cohort Profile: The National FINRISK Study. *Int. J. Epidemiol.* <https://doi.org/10.1093/ije/dyx239> (2017).
91. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience* **4**, 7 (2015).
92. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
93. 1000 Genomes Project Consortium. et al. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
94. Wang, K. et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res.* **17**, 1665–1674 (2007).
95. Lee, C. M. et al. UCSC Genome Browser enters 20th year. *Nucleic Acids Res.* **48**, D756–D761 (2020).
96. Bragin, E. et al. DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation. *Nucleic Acids Res.* **42**, D993–D1000 (2014).
97. Collins, R. L. et al. A cross-disorder dosage sensitivity map of the human genome. *Cell* **185**, 3041–3055.e25 (2022).
98. Köhler, S. et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. *Nucleic Acids Res.* **47**, D1018–D1027 (2019).
99. Abel, H. J. et al. Mapping and characterization of structural variation in 17,795 human genomes. *Nature* **583**, 83–89 (2020).
100. Collins, R. L. et al. A structural variation reference for medical and population genetics. *Nature* **581**, 444–451 (2020).
101. Sweeting, M. J., Sutton, A. J. & Lambert, P. C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat. Med.* **23**, 1351–1375 (2004).
102. Wakefield, J. Bayes factors for genome-wide association studies: comparison with P-values. *Genet. Epidemiol.* **33**, 79–86 (2009).
103. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* **44**, W90–W97 (2016).
104. Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**, 128 (2013).
105. Epi25 Collaborative. Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. *Am. J. Hum. Genet.* **105**, 267–282 (2019).
106. Villar, J. et al. The likeness of fetal growth and newborn size across non-isolated populations in the INTERGROWTH-21st Project: the Fetal Growth Longitudinal Study and Newborn Cross-Sectional Study. *Lancet Diabetes Endocrinol.* **2**, 781–792 (2014).

107. Lewis-Smith, D. et al. Modeling seizures in the Human Phenotype Ontology according to contemporary ILAE concepts makes big phenotypic data tractable. *Epilepsia* **62**, 1293–1305 (2021).
108. Greene, D., Richardson, S. & Turro, E. ontologyX: a suite of R packages for working with ontological data. *Bioinforma. Oxf. Engl.* **33**, 1104–1106 (2017).

Acknowledgements

This research was funded in whole, or in part, by the Wellcome Trust [203914/Z/16/Z], supporting D.L.S. For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. I.H. was supported by The Hartwell Foundation (Individual Biomedical Research Award), the National Institute for Neurological Disorders and Stroke (K02 NS112600), the Eunice Kennedy Shriver National Institute of Child Health and Human Development through the Intellectual and Developmental Disabilities Research Center (IDDR) at Children's Hospital of Philadelphia and the University of Pennsylvania (U54 HD086984), and by the German Research Foundation (HE5415/3-1, HE5415/5-1, HE5415/6-1, HE5415/7-1). Research reported in this publication was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001878), by the Institute for Translational Medicine and Therapeutics (ITMAT) at the Perelman School of Medicine of the University of Pennsylvania, and by Children's Hospital of Philadelphia through the Epilepsy NeuroGenetics Initiative (ENGIN). R.L.C. was supported by NHGRI T32HG002295 and NSF GRFP #2017240332. We thank the Epi25 principal investigators, local staff from individual cohorts, and all of the patients with epilepsy who participated in the study for making this global collaboration and resource possible to advance epilepsy genetics research. This work is part of the Centers for Common Disease Genomics (CCDG) program, funded by the National Human Genome Research Institute (NHGRI) and the National Heart, Lung, and Blood Institute (NHLBI). CCDG-funded Epi25 research activities at the Broad Institute, including genomic data generation in the Broad Genomics Platform, are supported by NHGRI grant UM1 HG008895 (PIs: Eric Lander, Stacey Gabriel, Mark Daly, Sekar Kathiresan). The Genome Sequencing Program efforts were also supported by NHGRI grant 5U01HG009088-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank the Stanley Center for Psychiatric Research at the Broad Institute for supporting the genomic data generation efforts and control sample aggregation.

Author contributions

Management of the study and content of the manuscript was the responsibility of D.L., C.L., L.M., D.L.S. and I.H. D.L. and C.L. designed the project, mentored all steps, coordinated the contributions, and guaranteed scientific coherence. D.L., C.L., L.M., T.B., M.M., D.L.S., R.T., R.L.C. and I.H. interpreted the results. The Epi25 Collaborative provided raw genotypic data for ~18,000 epilepsy patients and ~11,000 controls (Epi25 Collaborative cohort). M.T. provided a clean aggregated dataset of ~260,000 patients and ~460,000 controls

with CNV calls (neuropsychiatric disorders cohort). L.M.N., L.M., and C.L. carried out CNV calls and QC. L.M. performed the GWAS for the Epi25 dataset. R.L.C. performed the meta-analyses of the Epi25 GWAS with the neuropsychiatric disorders cohort. With the supervision of I.H. and R.T., D.L.S. developed the HPO-based phenome-wide association framework and applied it for each CNV. D.L.S. and S.G. cleaned the raw Epi25 phenotypic data. D.L.S., S.P., and J.X. illustrated the Epi25 phenome-wide association results. L.M., C.L., D.L., D.L.S., and R.L.C. wrote the manuscript. All authors including members of the Epi25 Collaborative, saw, commented, and approved the final draft.

Competing interests

R.H.T. received honoraria from Arvelle/Angelini, Bial, Eisai, GW Pharma/Jazz, Sanofi, UCB Pharma, and Zogenix, meeting support from LivaNova, Bial, Novartis, UCB Pharma, and unrestricted funding support from Arvelle/Angelini and UNEEG. M.E.T. receives research funding or reagents from Levo Therapeutics, Microsoft Inc., and Illumina Inc. All other authors report no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-023-39539-6>.

Correspondence and requests for materials should be addressed to Costin Leu or Dennis Lal.

Peer review information *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

¹Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, USA. ²Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. ³Clinical Neurosciences, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. ⁴The Epilepsy NeuroGenetics Initiative, Children's Hospital of Philadelphia, Philadelphia, PA, USA. ⁵Department of Biomedical and Health Informatics (DBHI), Children's Hospital of Philadelphia, Philadelphia, PA, USA. ⁶Center for Genomic Medicine, Massachusetts General Hospital, Boston, USA. ⁷Program in Medical and Population Genetics, Broad Institute of Massachusetts Institute of Technology (M.I.T.) and Harvard, Cambridge, USA. ⁸Cologne Center for Genomics, University of Cologne, Cologne, Germany. ⁹Department of Neurology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. ¹⁰Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London, UK. ¹¹Stanley Center for Psychiatric Research, Broad Institute of Harvard and M.I.T., Cambridge, MA, USA. ¹²Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, US. ¹⁷⁰These authors

contributed equally: Ludovica Montanucci, David Lewis-Smith, Ryan L. Collins, Lisa-Marie Niestroj. ¹⁷¹These authors jointly supervised this work: Costin Leu, Dennis Lal. ✉ e-mail: costin.leu@uth.tmc.edu; Dennis.Lal@uth.tmc.edu

Epi25 Collaborative

Columbia University Institute for Genomic Medicine analysis group Joshua E. Motelow¹³, Gundula Povysil¹³, Ryan S. Dhindsa¹³, Kate E. Stanley¹³, Andrew S. Allen¹⁴ & David B. Goldstein¹³

Epi25 sequencing, analysis, project management, and browser development at the Broad Institute Yen-Chen Anne Feng^{11,15,16,17}, Daniel P. Howrigan^{11,15,17}, Liam E. Abbott^{11,15,17}, Katherine Tashman^{11,15,17}, Felecia Cerrato¹¹, Caroline Cusick¹¹, Tarjinder Singh^{11,15,17}, Henrike Heyne^{11,15,17}, Andrea E. Byrnes^{11,15,17}, Claire Churchhouse^{11,15,17}, Nick Watts^{11,15,17}, Matthew Solomonson^{11,15,17}, Dennis Lal^{1,11}, Namrata Gupta¹⁷ & Benjamin M. Neale^{11,15,17}

Epi25 executive committee Samuel F. Berkovic¹⁸, Holger Lerche¹⁹, David B. Goldstein¹³ & Daniel H. Lowenstein²⁰

Epi25 strategy, phenotyping, analysis, informatics, and project management committees

Samuel F. Berkovic¹⁸, Holger Lerche¹⁹, David B. Goldstein¹³, Daniel H. Lowenstein²⁰, Gianpiero L. Cavalleri^{21,22}, Patrick Cossette²³, Chris Cotsapas²⁴, Peter De Jonghe^{25,26,27}, Tracy Dixon-Salazar²⁸, Renzo Guerrini²⁹, Hakon Hakonarson³⁰, Erin L. Heinzen¹³, Ryan S. Dhindsa¹³, Kate E. Stanley¹³, Ingo Helbig^{5,9,30}, Patrick Kwan^{31,32}, Anthony G. Marson³³, Slavé Petrovski^{32,34}, Sitharthan Kamalakaran¹³, Sanjay M. Sisodiya^{35,36}, Randy Stewart³⁷, Sarah Weckhuysen^{25,26,27}, Chantal Depondt³⁸, Dennis J. Dlugos^{9,30}, Ingrid E. Scheffer¹⁸, Pasquale Striano^{39,40}, Catharine Freyer²⁰, Roland Krause⁴¹, Patrick May⁴¹, Kevin McKenna²⁰, Brigid M. Regan¹⁸, Caitlin A. Bennett¹⁸, Stephanie L. Leech¹⁸, Costin Leu^{1,11,35,36} & David Lewis-Smith^{2,3,5,30}

Authors from individual Epi25 cohorts:

Australia: Melbourne (AUSAUS) Samuel F. Berkovic¹⁸, Ingrid E. Scheffer¹⁸, Brigid M. Regan¹⁸, Caitlin A. Bennett¹⁸ & Stephanie L. Leech¹⁸

Australia: Royal Melbourne (AUSRMB) Terence J. O'Brien^{31,32}, Slavé Petrovski^{32,34}, Marian Todaro^{31,32} & Patrick Kwan^{31,32}

Belgium: Antwerp (BELATW) Sarah Weckhuysen^{25,26,27}, Peter De Jonghe^{25,26,27} & Hannah Stamberger^{25,26,27}

Belgium: Brussels (BELULB) Chantal Depondt³⁸

Canada: Andrade (CANUTN) Danielle M. Andrade^{42,43}, Quratulain Zulfiqar Ali⁴² & Tara R. Sadoway⁴³

Switzerland: Bern (CHEUBB) Heinz Krestel²⁴ & André Schaller⁴⁴

Cyprus (CYPCYP) Savvas S. Papacostas⁴⁵, Ioanna Kousiappa⁴⁵, George A. Tanteles⁴⁶ & Christou Yiolanda⁴⁵

Czech Republic: Prague (CZEMTH) Katalin Štěrbová⁴⁷, Markéta Vlčková⁴⁷, Lucie Sedláčková⁴⁷ & Petra Lašuthová⁴⁷

Germany: Frankfurt/Marburg (DEUPUM) Karl Martin Klein^{48,49,50,51}, Felix Rosenow^{48,49,50}, Philipp S. Reif^{48,49,50} & Susanne Knake^{49,50}

Germany: Giessen (DEUUGS) Bernd A. Neubauer⁵², Friedrich Zimprich⁵³, Martha Feucht⁵² & Eva Reinthaler⁵³

Germany: Bonn (DEUUKB) Wolfram S. Kunz^{54,55}, Gábor Zsurka^{54,55}, Rainer Surges⁵⁵, Tobias H. Baumgartner⁵⁵ & Randi von Wrede⁵⁵

Germany: Kiel (DEUUKL) Ingo Helbig^{30,56,57}, Karl Martin Klein^{48,49,50,51}, Manuela Pendziwiat^{56,57}, Hiltrud Muhle⁵⁷, Annika Rademacher⁵⁷, Andreas van Baalen⁵⁷, Sarah von Spiczak^{57,58}, Ulrich Stephani⁵⁷, Zaid Afawi⁵⁹, Amos D. Korczyn⁶⁰, Moien Kanaan⁶¹, Christina Canavati⁶¹, Gerhard Kurlemann⁶², Karen Müller-Schlüter⁶³, Gerhard Kluger^{64,65}, Martin Häusler⁶⁶ & Ilan Blatt^{60,67}

Germany: Leipzig (DEUULG) Johannes R. Lemke⁶⁸ & Ilona Krey⁶⁸

Germany: Tuebingen (DEUUTB) Holger Lerche¹⁹, Yvonne G. Weber^{19,69}, Stefan Wolking¹⁹, Felicitas Becker^{19,70}, Stephan Lauxmann¹⁹, Christian Bosselmann¹⁹, Josua Kegele¹⁹, Christian Hengsbach¹⁹, Sarah Rau¹⁹, Bernhard J. Steinhoff⁷¹, Andreas Schulze-Bonhage⁷², Ingo Borggräfe^{73,74}, Christoph J. Schankin^{75,76}, Susanne Schubert-Bast⁷², Herbert Schreiber⁷⁷, Thomas Mayer⁷⁸, Rudolf Korinthenberg⁷⁹, Knut Brockmann⁸⁰, Markus Wolff⁸¹, Gerhard Kurlemann⁸², Dieter Dennig⁸³, Rene Madeleyn⁸⁴ & Josua Kegele¹⁹

Finland: Kuopio (FINKPH) Reetta Kälviäinen^{85,86}, Anni Saarela⁸⁵ & Oskari Timonen⁸⁶

Finland: Helsinki (FINUVH) Tarja Linnankivi⁸⁷ & Anna-Elina Lehesjoki⁸⁸

France: Lyon (FRALYU) Sylvain Rheims^{89,90}, Gaetan Lesca⁹¹, Philippe Ryvlin⁹², Louis Maillard⁹³, Luc Valton⁹⁴, Philippe Derambure⁹⁵, Fabrice Bartolomei⁹⁶, Edouard Hirsch⁹⁷, Véronique Michel⁹⁸ & Francine Chassoux⁹⁹

Wales: Swansea (GBRSWU) Mark I. Rees¹⁰⁰, Seo-Kyung Chung^{100,101}, William O. Pickrell¹⁰², Robert H. W. Powell¹⁰³, Mark D. Baker¹⁰², Beata Fonferko-Shadrach¹⁰², Charlotte Lawthom¹⁰⁴ & Joe Anderson¹⁰⁴

UK: UCL (GBRUCU) Sanjay M. Sisodiya^{35,36}, Natascha Schneider^{35,36}, Simona Balestrini^{35,36}, Sara Zagaglia^{35,36} & Vera Braatz^{35,36}

UK: Imperial/Liverpool (GBRUNL) Anthony G. Marson³³, Michael R. Johnson¹⁰⁵, Pauls Auce¹⁰⁶ & Graeme J. Sills¹⁰⁷

Hong Kong (HKGHKK) Patrick Kwan^{31,32,108}, Larry W. Baum¹⁰⁹, Pak C. Sham¹⁰⁹, Stacey S. Cherny¹¹⁰ & Colin H. T. Lui¹¹¹

Ireland: Dublin (IRLRICI) Gianpiero L. Cavalleri^{21,22}, Norman Delanty^{21,22,112}, Colin P. Doherty^{22,113}, Arif Shukralla^{22,112}, Hany El-Naggar^{21,22,112} & Peter Widdess-Walsh^{21,22,112}

Croatia (HRVUZG) Nina Barišić¹¹⁴

Italy: Milan (ITAICB) Laura Canafoglia¹¹⁵, Silvana Franceschetti¹¹⁶, Barbara Castellotti¹¹⁷, Tiziana Granata¹¹⁸ & Francesca Ragona¹¹⁸

Italy: Genova (ITAIGI) Pasquale Striano^{39,40}, Federico Zara^{39,40}, Michele Iacomino³⁹, Antonella Riva^{39,40}, Francesca Madia^{39,40}, Maria Stella Vari³⁹, Vincenzo Salpietro³⁹, Marcello Scala³⁹, Maria Margherita Mancardi³⁹, Nobili Lino³⁹, Elisa Amadori³⁹ & Thea Giacomini³⁹

Italy: Bologna (ITAUBG) Francesca Bisulli^{119,120}, Tommaso Pippucci¹²¹, Laura Licchetta^{119,120}, Raffaella Minardi¹¹⁹, Paolo Tinuper^{119,120}, Lorenzo Muccioli^{119,120} & Barbara Mostacci¹¹⁹

Italy: Catanzaro (ITAUMC) Antonio Gambardella¹²², Angelo Labate¹²², Grazia Annesi¹²³, Lorella Manna¹²³ & Monica Gagliardi¹²³

Italy: Florence (ITAUMR) Renzo Guerrini²⁹, Elena Parrini²⁹, Davide Mei²⁹, Annalisa Vetro²⁹, Claudia Bianchini²⁹, Martino Montomoli²⁹, Viola Doccini²⁹ & Carmen Barba²⁹

Japan: Fukuoka (JPNFKA) Shinichi Hirose¹²⁴ & Atsushi Ishii¹²⁴

Japan: RIKEN Institute (JPNRKI) Toshimitsu Suzuki^{125,126}, Yushi Inoue¹²⁷ & Kazuhiro Yamakawa^{125,126}

Lebanon: Beirut (LEBABM) Ahmad Beydoun¹²⁸, Wassim Nasreddine¹²⁸ & Nathalie Khoueiry-Zgheib¹²⁹

Lithuania (LTUHHK) Birute Tumiene^{130,131} & Algirdas Utkus^{130,131}

New Zealand: Otago (NZLUTO) Lynette G. Sadleir¹³² & Chontelle King¹³²

Turkey: Bogazici (TURBZU) S. Hande Caglayan¹³³, Mutluay Arslan¹³⁴, Zuhale Yapici¹³⁵, Pinar Topaloglu¹³⁵, Bulent Kara¹³⁶, Uluc Yis¹³⁶, Dilsad Turkdogan¹³⁶ & Asli Gundogdu-Eken¹³³

Turkey: Istanbul (TURIBU) Nerses Bebek^{137,138}, Sibel Uğur-İşeri¹³⁸, Betül Baykan¹³⁷, Barış Salman¹³⁸, Garen Haryanyan¹³⁷, Emrah Yücesan¹³⁹, Yeşim Kesim¹³⁷ & Çiğdem Özkara¹⁴⁰

Taiwan (TWNCGM) Meng-Han Tsai¹⁴¹, Chen-Jui Ho¹⁴¹, Chih-Hsiang Lin¹⁴¹, Kuang-Lin Lin¹⁴² & I-Jun Chou¹⁴²

USA: BCH (USABCH) Annapurna Poduri^{143,144}, Beth R. Shiedley^{143,144} & Catherine Shain^{143,144}

USA: Baylor College of Medicine (USABLC) Jeffrey L. Noebels¹⁴⁵ & Alicia Goldman¹⁴⁵

USA: Cleveland Clinic (USACCF) Robyn M. Busch^{1,12,146}, Lara Jehi^{12,146}, Imad M. Najm^{12,146}, Dennis Lal^{1,12}, Lisa Ferguson¹² & Jean Khoury^{12,146}

USA: Cincinnati Children's Hospital Medical Center (USACCH) Tracy A. Glauser¹⁴⁷ & Peggy O. Clark¹⁴⁷

USA: Philadelphia/CHOP (USACHP) and Philadelphia/Rowan (USACRW) Russell J. Buono^{30,148,149}, Thomas N. Ferraro¹⁴⁸, Michael R. Sperling¹⁴⁹, Dennis J. Dlugos^{30,150}, Warren Lo¹⁵⁰, Michael Privitera¹⁵¹, Jacqueline A. French¹⁵², Patrick Cossette²³, Steven Schachter¹⁵³ & Hakon Hakonarson³⁰

USA: EPGP (USAEGP) Daniel H. Lowenstein²⁰, Ruben I. Kuzniecky¹⁵⁴, Dennis J. Dlugos^{9,30} & Orrin Devinsky¹⁵²

USA: NYU HEP (USAHEP) Daniel H. Lowenstein²⁰, Ruben I. Kuzniecky¹⁵⁴, Jacqueline A. French¹⁵² & Manu Hegde²⁰

USA: Nationwide Children's Hospital (USANCH) David A. Greenberg¹⁵⁵

USA: Penn/CHOP (USAUPN) Ingo Helbig^{5,9,30}, Colin A. Ellis⁹, Ethan Goldberg^{4,30}, Katherine L. Helbig^{4,30}, David Lewis-Smith^{2,3,5,30}, Mahgenn Cosico^{4,30}, Priya Vaidiswaran^{4,30} & Eryn Fitch^{4,30}

Kenya: Kilifi; South Africa: Agincourt; Ghana: Kintampo (KENKIL, GHAKNT, ZAFAGN) Charles R. J. C. Newton^{156,157,158}, Symon M. Kariuki^{156,157,158}, Ryan G. Wagner^{159,160,161} & Seth Owusu-Agyei^{162,163}

USA: Massachusetts General Hospital (USAMGH) Andrew J. Cole¹⁶⁴, Christopher M. McGraw¹⁶⁴ & S. Anthony Siena¹⁶⁵

USA: Vanderbilt University Medical Centre (USAVAN) Lea Davis^{166,167,168,169}, Donald Hucks^{166,169}, Annika Faucon¹⁶⁹, David Wu¹⁶⁹, Bassel W. Abou-Khalil¹⁶⁹, Kevin Haas¹⁶⁹ & Randip S. Taneja¹⁶⁹

¹³Institute for Genomic Medicine, Columbia University, New York, NY 10032, USA. ¹⁴Division of Integrative Genomics, Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 27710, USA. ¹⁵Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. ¹⁶Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. ¹⁷Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA. ¹⁸Epilepsy Research Centre, Department of Medicine, University of Melbourne, Victoria, Australia. ¹⁹Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany. ²⁰Department of Neurology, University of California, San Francisco, CA 94110, USA. ²¹School of Pharmacy and Biomolecular Sciences, The Royal College of Surgeons in Ireland, Dublin, Ireland. ²²The FutureNeuro Research Centre, Dublin, Ireland. ²³University of Montreal, Montreal, QC H3T 1J4, Canada. ²⁴School of Medicine, Yale University, New Haven, CT 06510, USA. ²⁵Neurogenetics Group, Center for Molecular Neurology, VIB Antwerp, Belgium. ²⁶Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ²⁷Division of Neurology, Antwerp University Hospital, Antwerp, Belgium. ²⁸LGS Foundation, NY New York 11716, USA. ²⁹Pediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Children's Hospital A. Meyer, University of Florence, Florence, Italy. ³⁰Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. ³¹Department of Neuroscience, Central Clinical School, Monash University, Alfred Hospital, Melbourne, Australia. ³²Departments of Medicine and Neurology, University of Melbourne, Royal Melbourne Hospital, Parkville, Australia. ³³Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK. ³⁴Centre for Genomics Research, Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, UK. ³⁵Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK. ³⁶Chalfont Centre for Epilepsy, Chalfont St Peter, UK. ³⁷National Institute of Neurological Disorders and Stroke, Bethesda, MD 20852, USA. ³⁸Department of Neurology, Université Libre de Bruxelles, Brussels, Belgium. ³⁹IRCCS "G. Gaslini" Institute, Genova, Italy. ⁴⁰Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy. ⁴¹Luxembourg Centre for Systems Biomedicine, University Luxembourg, Esch-sur-Alzette, Luxembourg. ⁴²Department of Neurology, Toronto Western Hospital, Toronto, ON M5T 2S8, Canada. ⁴³University Health Network, University of Toronto, Toronto, ON, Canada. ⁴⁴Institute of Human Genetics, Bern University Hospital, Bern, Switzerland. ⁴⁵Department of Neurobiology and Clinical Neurophysiology (Epilepsy Center), The Cyprus Institute of Neurology and Genetics, 2370 Nicosia, Cyprus. ⁴⁶Department of Clinical Genetics, The Cyprus Institute of Neurology and Genetics, 2370 Nicosia, Cyprus. ⁴⁷Department of Paediatric Neurology, 2nd Faculty of Medicine, Charles University and Motol Hospital, Prague, Czech Republic. ⁴⁸Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, Goethe University Frankfurt, Frankfurt, Germany. ⁴⁹Epilepsy Center Hessen-Marburg, Department of Neurology, Philipps University Marburg, Marburg, Germany. ⁵⁰LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe University Frankfurt, Frankfurt, Germany.

⁵¹Departments of Clinical Neurosciences, Medical Genetics and Community Health Sciences, Hotchkiss Brain Institute & Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. ⁵²Pediatric Neurology, Children's Hospital, Giessen, Germany. ⁵³Department of Neurology, Medical University of Vienna, Vienna, Austria. ⁵⁴Institute of Experimental Epileptology and Cognition Research, University Bonn, 53127 Bonn, Germany. ⁵⁵Department of Epileptology, University Bonn, 53127 Bonn, Germany. ⁵⁶Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany. ⁵⁷Department of Neuropediatrics, Christian-Albrechts-University of Kiel, 24105 Kiel, Germany. ⁵⁸DRK-Northern German Epilepsy Centre for Children and Adolescents, 24223 Schwentinental-Raisdorf, Germany. ⁵⁹Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel. ⁶⁰Tel-Aviv University Sackler Faculty of Medicine, Ramat Aviv 69978, Israel. ⁶¹Hereditary Research Lab, Bethlehem University, Bethlehem, Palestine. ⁶²Bonifatius Hospital Lingen, Neuropediatrics Wilhelmstrasse 13, 49808 Lingen, Germany. ⁶³Epilepsy Center for Children, University Hospital Neuruppin, Brandenburg Medical School, Neuruppin, Germany. ⁶⁴Neuropediatric Clinic and Clinic for Neurorehabilitation, Epilepsy Center for Children and Adolescents, Vogtareuth, Germany. ⁶⁵Research Institute Rehabilitation / Transition / Palliation, PMU Salzburg, Austria. ⁶⁶Division of Neuropediatrics and Social Pediatrics, Department of Pediatrics, University Hospital, RWTH Aachen, Aachen, Germany. ⁶⁷Department of Neurology, Sheba Medical Center, Ramat Gan, Israel. ⁶⁸Institute of Human Genetics, Leipzig, Germany. ⁶⁹Department of Epileptology and Neurology, University of Aachen, Aachen, Germany. ⁷⁰Department of Neurology, University of Ulm, Ulm, Germany. ⁷¹Epilepsy Center Kork, Kehl, Germany. ⁷²Department of Epileptology, University Hospital Freiburg, Freiburg, Germany. ⁷³Department of Pediatric Neurology, Ludwig Maximilians University, Munchen, Germany. ⁷⁴Dr von Hauner Childrens Hospital, Munich, Germany. ⁷⁵Department of Neurology, Ludwig Maximilians University, Munchen, Germany. ⁷⁶Department of Neurology, University Hospital Bern, Bern, Switzerland. ⁷⁷Neurological Practice Center & Neupoint Patient Academy, Ulm, Germany. ⁷⁸Epilepsy Center Kleinwachau, Radeberg, Germany. ⁷⁹Department of Neuropediatrics and Muscular Disorders, University Hospital Freiburg, Freiburg, Germany. ⁸⁰University Children's Hospital, Göttingen, Germany. ⁸¹Department of Pediatric Neurology & Developmental Medicine, University Childrens Hospital, Tübingen, Germany. ⁸²Department of Neuropediatrics, Westfälische Wilhelms University, Munster, Germany. ⁸³Private Neurological Practice, Stuttgart, Germany. ⁸⁴Department of Pediatrics, Filderklinik, Filderstadt, Germany. ⁸⁵Epilepsy Center, Kuopio University Hospital, Kuopio, Finland. ⁸⁶Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. ⁸⁷Child Neurology, New Children's Hospital and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁸⁸Medicum, University of Helsinki, Helsinki, Finland and Folkhälsan Research Center, Helsinki, Finland. ⁸⁹Department of Functional Neurology and Epileptology, Hospices Civils de Lyon and University of Lyon, Lyon, France. ⁹⁰Lyon's Neuroscience Research Center, INSERM U1028 / CNRS UMR 5292, Lyon, France. ⁹¹Department of Clinical Genetics, Hospices Civils de Lyon and University of Lyon, Lyon, France. ⁹²Department of Clinical Neurosciences, Centre Hospitalo-Universitaire Vaudois, Lausanne, Switzerland. ⁹³Neurology Department, University Hospital of Nancy, UMR 7039, CNRS, Lorraine University, Nancy, France. ⁹⁴Clinical Neurophysiology and Epilepsy Unit, Department of Neurology, University Hospital of Toulouse, Toulouse, France. ⁹⁵Department of Clinical Neurophysiology, Lille University Medical Center, EA 1046, University of Lille, Lille, France. ⁹⁶Clinical Neurophysiology and Epileptology Department, Timone Hospital, Marseille, France. ⁹⁷Department of Neurology, University Hospital of Strasbourg, Strasbourg, France. ⁹⁸Department of Neurology, Hôpital Pellegrin, Bordeaux, France. ⁹⁹Epilepsy Unit, Department of Neurosurgery, Centre Hospitalier Sainte-Anne and University Paris Descartes, Paris, France. ¹⁰⁰Faculty of Medicine and Health, University of Sydney, Sydney, Australia. ¹⁰¹Kids Neuroscience Centre, Kids Research, Children Hospital at Westmead, Sydney, NSW, Australia. ¹⁰²Swansea University Medical School, Swansea University, SA2 8PP Swansea, UK. ¹⁰³Department of Neurology, Morriston Hospital, Swansea Bay University Health Board, Swansea, Wales, UK. ¹⁰⁴Neurology Department, Aneurin Bevan University Health Board, Newport, Wales, UK. ¹⁰⁵Division of Brain Sciences, Imperial College London, London, UK. ¹⁰⁶Department of Neurology, Walton Centre NHS Foundation Trust, Liverpool, UK. ¹⁰⁷School of Life Sciences, University of Glasgow, Glasgow, UK. ¹⁰⁸Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, China. ¹⁰⁹Department of Psychiatry, University of Hong Kong, Hong Kong, China. ¹¹⁰Department of Epidemiology and Preventive Medicine and Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ¹¹¹Department of Medicine, Tseung Kwan O Hospital, Hong Kong, China. ¹¹²The Department of Neurology, Beaumont Hospital, Dublin, Ireland. ¹¹³Neurology Department, St. James Hospital, Dublin, Ireland. ¹¹⁴Department of Pediatric University Hospital centre Zagreb, Zagreb, Croatia. ¹¹⁵Integrated Diagnostics for Epilepsy, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. ¹¹⁶Neurophysiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. ¹¹⁷Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. ¹¹⁸Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. ¹¹⁹IRCCS, Institute of Neurological Sciences of Bologna, Bologna, Italy. ¹²⁰Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. ¹²¹Medical Genetics Unit, Polyclinic Sant'Orsola-Malpighi University Hospital, Bologna, Italy. ¹²²Institute of Neurology, Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy. ¹²³Institute of Molecular Bioimaging and Physiology, CNR, Section of Germaneto, Catanzaro, Italy. ¹²⁴Department of Pediatrics, School of Medicine, Fukuoka University, Fukuoka, Japan. ¹²⁵Laboratory for Neurogenetics, RIKEN Center for Brain Science, Saitama, Japan. ¹²⁶Department of Neurodevelopmental Disorder Genetics, Institute of Brain Science, Nagoya City University Graduate School of Medical Science, Nagoya, Aichi, Japan. ¹²⁷National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorder, Shizuoka, Japan. ¹²⁸Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon. ¹²⁹Department of Pharmacology and Toxicology, American University of Beirut Faculty of Medicine, Beirut, Lebanon. ¹³⁰Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. ¹³¹Centre for Medical Genetics, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. ¹³²Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand. ¹³³Department of Molecular Biology and Genetics, Bogaziçi University, Istanbul, Turkey. ¹³⁴Department of Child Neurology, Gulhane Education and Research Hospital, Health Sciences University, Ankara, Turkey. ¹³⁵Department of Child Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. ¹³⁶Department of Child Neurology, Medical School, Marmara University, Istanbul, Turkey. ¹³⁷Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. ¹³⁸Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. ¹³⁹Bezmialem Vakif University, Institute of Life Sciences and Biotechnology, Istanbul, Turkey. ¹⁴⁰Department of Neurology, Faculty of Medicine, Cerrahpaşa University Istanbul, Istanbul, Turkey. ¹⁴¹Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. ¹⁴²Department of Pediatric Neurology, Chang Gung Memorial Hospital, Taoyuan, Taiwan. ¹⁴³Epilepsy Genetics Program, Department of Neurology, Boston Children's Hospital, Boston, MA 02115, USA. ¹⁴⁴Department of Neurology, Harvard Medical School, Boston, MA 02115, USA. ¹⁴⁵Neurology, Baylor College of Medicine, Texas, US. ¹⁴⁶Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA. ¹⁴⁷Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. ¹⁴⁸Cooper Medical School of Rowan University, Camden, NJ 08103, USA. ¹⁴⁹Thomas Jefferson University, Philadelphia, PA 19107, USA. ¹⁵⁰Nationwide Children's Hospital, Columbus, OH 3205, USA. ¹⁵¹University of Cincinnati, Cincinnati, OH 45220, USA. ¹⁵²Department of Neurology, New York University, New York, NY, USA. ¹⁵³Beth Israel Deaconess/Harvard, Boston, MA 02115, USA. ¹⁵⁴Department of Neurology, Hofstra-Northwell Medical School, New York, NY 11549, USA. ¹⁵⁵Department of Pediatrics, Ohio State Wexner Medical Center, Battelle Center for Mathematical Medicine, Columbus, Ohio, USA. ¹⁵⁶Neuroscience Unit, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. ¹⁵⁷Department of Public Health, Pwani University, Kilifi, Kenya. ¹⁵⁸Department of Psychiatry, University of Oxford, Oxford, UK. ¹⁵⁹MRC/Wits Rural Public Health & Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the

Witwatersrand, Johannesburg, South Africa. ¹⁶⁰Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden. ¹⁶¹Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden. ¹⁶²Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana. ¹⁶³University of Health and Allied Science in Ho, Ho, Ghana. ¹⁶⁴Neurology, Massachusetts General Hospital, Boston, MA, USA. ¹⁶⁵Medical School, Nova Southeastern University, Fort Lauderdale, FL, USA. ¹⁶⁶Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. ¹⁶⁷Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. ¹⁶⁸Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA. ¹⁶⁹Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, USA.